NZ763587B2 - Methods, kits and apparatus for expanding a population of cells - Google Patents
Methods, kits and apparatus for expanding a population of cells Download PDFInfo
- Publication number
- NZ763587B2 NZ763587B2 NZ763587A NZ76358715A NZ763587B2 NZ 763587 B2 NZ763587 B2 NZ 763587B2 NZ 763587 A NZ763587 A NZ 763587A NZ 76358715 A NZ76358715 A NZ 76358715A NZ 763587 B2 NZ763587 B2 NZ 763587B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- cells
- agent
- streptavidin
- binding
- reagent
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract description 82
- 210000004027 cell Anatomy 0.000 claims abstract description 501
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 433
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 368
- 230000004913 activation Effects 0.000 claims abstract description 63
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 42
- 230000027455 binding Effects 0.000 claims description 476
- 108010090804 Streptavidin Proteins 0.000 claims description 187
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 87
- 230000005526 G1 to G0 transition Effects 0.000 claims description 76
- 108010018381 streptavidin-binding peptide Proteins 0.000 claims description 49
- 150000001413 amino acids Chemical class 0.000 claims description 31
- 235000020958 biotin Nutrition 0.000 claims description 30
- 239000011616 biotin Substances 0.000 claims description 30
- 229960002685 biotin Drugs 0.000 claims description 30
- 239000012504 chromatography matrix Substances 0.000 claims description 29
- 238000004587 chromatography analysis Methods 0.000 claims description 28
- 238000001042 affinity chromatography Methods 0.000 claims description 26
- 239000011159 matrix material Substances 0.000 claims description 20
- 230000004936 stimulating effect Effects 0.000 claims description 16
- 238000002523 gelfiltration Methods 0.000 claims description 15
- 230000003100 immobilizing effect Effects 0.000 claims description 11
- 238000001641 gel filtration chromatography Methods 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 151
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 139
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 139
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 78
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 78
- 230000002441 reversible effect Effects 0.000 description 73
- 108090000765 processed proteins & peptides Proteins 0.000 description 64
- 108090001008 Avidin Proteins 0.000 description 54
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 52
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 52
- 239000000427 antigen Substances 0.000 description 47
- 108091007433 antigens Proteins 0.000 description 47
- 102000036639 antigens Human genes 0.000 description 47
- 230000000638 stimulation Effects 0.000 description 41
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 39
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 39
- 238000002360 preparation method Methods 0.000 description 39
- 239000011324 bead Substances 0.000 description 38
- 238000000338 in vitro Methods 0.000 description 36
- 150000002500 ions Chemical class 0.000 description 36
- 102000005962 receptors Human genes 0.000 description 36
- 108020003175 receptors Proteins 0.000 description 36
- 230000035755 proliferation Effects 0.000 description 31
- 102000000584 Calmodulin Human genes 0.000 description 29
- 108010041952 Calmodulin Proteins 0.000 description 29
- 239000013642 negative control Substances 0.000 description 29
- 238000002474 experimental method Methods 0.000 description 26
- 239000000203 mixture Substances 0.000 description 26
- 108010002350 Interleukin-2 Proteins 0.000 description 25
- 102000000588 Interleukin-2 Human genes 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 25
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 23
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 23
- 239000013641 positive control Substances 0.000 description 23
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 22
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 238000007792 addition Methods 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 239000006143 cell culture medium Substances 0.000 description 17
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 16
- 102100033467 L-selectin Human genes 0.000 description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 14
- 229910052791 calcium Inorganic materials 0.000 description 14
- 239000011575 calcium Substances 0.000 description 14
- 230000010261 cell growth Effects 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 13
- 235000000638 D-biotin Nutrition 0.000 description 13
- 239000011665 D-biotin Substances 0.000 description 13
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 210000003719 b-lymphocyte Anatomy 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 239000003446 ligand Substances 0.000 description 12
- 210000003071 memory t lymphocyte Anatomy 0.000 description 12
- 108091006905 Human Serum Albumin Proteins 0.000 description 11
- 102000008100 Human Serum Albumin Human genes 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 101150013553 CD40 gene Proteins 0.000 description 10
- 230000003213 activating effect Effects 0.000 description 10
- 238000010494 dissociation reaction Methods 0.000 description 10
- 230000005593 dissociations Effects 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 241000701022 Cytomegalovirus Species 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 9
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 102000000844 Cell Surface Receptors Human genes 0.000 description 8
- 108010001857 Cell Surface Receptors Proteins 0.000 description 8
- 102000005720 Glutathione transferase Human genes 0.000 description 8
- 108010070675 Glutathione transferase Proteins 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000002427 irreversible effect Effects 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 7
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 7
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 7
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 7
- 229910001424 calcium ion Inorganic materials 0.000 description 7
- 239000002738 chelating agent Substances 0.000 description 7
- -1 dextran Chemical class 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- 210000000822 natural killer cell Anatomy 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000006073 displacement reaction Methods 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 229910021645 metal ion Inorganic materials 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241000701161 unidentified adenovirus Species 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 5
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 5
- 108010078791 Carrier Proteins Proteins 0.000 description 5
- 108090000172 Interleukin-15 Proteins 0.000 description 5
- 102000043129 MHC class I family Human genes 0.000 description 5
- 108091054437 MHC class I family Proteins 0.000 description 5
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 108091008874 T cell receptors Proteins 0.000 description 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
- 150000001615 biotins Chemical class 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 230000032823 cell division Effects 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 229960001484 edetic acid Drugs 0.000 description 5
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 4
- 108010091938 HLA-B7 Antigen Proteins 0.000 description 4
- 102000019298 Lipocalin Human genes 0.000 description 4
- 108050006654 Lipocalin Proteins 0.000 description 4
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000009920 chelation Effects 0.000 description 4
- 102000021178 chitin binding proteins Human genes 0.000 description 4
- 108091011157 chitin binding proteins Proteins 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000012510 hollow fiber Substances 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000031146 intracellular signal transduction Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 108010082808 4-1BB Ligand Proteins 0.000 description 3
- 108010083359 Antigen Receptors Proteins 0.000 description 3
- 102000006306 Antigen Receptors Human genes 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 108010020195 FLAG peptide Proteins 0.000 description 3
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 3
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000006249 magnetic particle Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 102000008102 Ankyrins Human genes 0.000 description 2
- 108010049777 Ankyrins Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000003930 C-Type Lectins Human genes 0.000 description 2
- 108090000342 C-Type Lectins Proteins 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 102100033620 Calponin-1 Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 240000003550 Eusideroxylon zwageri Species 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 229910001428 transition metal ion Inorganic materials 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- AUTOLBMXDDTRRT-JGVFFNPUSA-N (4R,5S)-dethiobiotin Chemical compound C[C@@H]1NC(=O)N[C@@H]1CCCCCC(O)=O AUTOLBMXDDTRRT-JGVFFNPUSA-N 0.000 description 1
- DEQPBRIACBATHE-FXQIFTODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-2-iminopentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCC(=N)C(=O)O)SC[C@@H]21 DEQPBRIACBATHE-FXQIFTODSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000002110 C2 domains Human genes 0.000 description 1
- 108050009459 C2 domains Proteins 0.000 description 1
- 108010005327 CD19-specific chimeric antigen receptor Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 235000004035 Cryptotaenia japonica Nutrition 0.000 description 1
- 108010025905 Cystine-Knot Miniproteins Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000012545 EGF-like domains Human genes 0.000 description 1
- 108050002150 EGF-like domains Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000002090 Fibronectin type III Human genes 0.000 description 1
- 108050009401 Fibronectin type III Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 102210024302 HLA-B*0702 Human genes 0.000 description 1
- 108010078301 HLA-B*07:02 antigen Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 102000013271 Hemopexin Human genes 0.000 description 1
- 108010026027 Hemopexin Proteins 0.000 description 1
- 101000757556 Homo sapiens Apolipoprotein D Proteins 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000946124 Homo sapiens Lipocalin-1 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 description 1
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 241000288904 Lemur Species 0.000 description 1
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 1
- 102000010954 Link domains Human genes 0.000 description 1
- 108050001157 Link domains Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 102100037369 Nidogen-1 Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 102000000395 SH3 domains Human genes 0.000 description 1
- 108050008861 SH3 domains Proteins 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102000000890 Somatomedin B domains Human genes 0.000 description 1
- 108050007913 Somatomedin B domains Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000007641 Trefoil Factors Human genes 0.000 description 1
- 235000015724 Trifolium pratense Nutrition 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000003809 bile pigment Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940068840 d-biotin Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000056778 human APOD Human genes 0.000 description 1
- 102000047202 human LCN2 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000002824 mRNA display Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002500 microbody Anatomy 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108091005725 scavenger receptor cysteine-rich superfamily Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229950001790 tendamistat Drugs 0.000 description 1
- 108010037401 tendamistate Proteins 0.000 description 1
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/02—Separating microorganisms from the culture medium; Concentration of biomass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/12—Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/52—CD40, CD40-ligand (CD154)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
Abstract
The present invention relates to in vitro-methods of expanding a population of cells such as lymphocytes, comprising contacting a sample comprising a population of cells with a multimerization reagent. The multimerization reagent has reversibly immobilized thereon (bound thereto) a first agent that provides a primary activation signal to the cells and optionally, a second agent that provides a co-stimulatory signal. The invention also provides multimerization reagents, kits, arrangements and an apparatus for expanding cells. provides a primary activation signal to the cells and optionally, a second agent that provides a co-stimulatory signal. The invention also provides multimerization reagents, kits, arrangements and an apparatus for expanding cells.
Description
S, KITS AND TUS FOR EXPANDING A POPULATION OF
CELLS
CROSS-REFERENCE TO RELATED APPLICATIONS
The t invention claims the benefit of priority to US provisional patent
ation 61/980,506 “Methods, Kits And Apparatus For Expanding A Population Of Cells ”
filed with the US Patent and Trademark Office on 16 April 2014, the contents of which is
hereby incorporated by reference in its entirety for all purposes.
FIELD OF THE INVENTION
The t invention relates to the expansion (proliferation) of a tion of
cells such as a population of lymphocytes. The invention in general provides novel methods
and reagents for the ion (proliferation) of cell populations that require binding of a
receptor binding molecule (such as a first agent as described herein) to a receptor molecule on
the surface of the cells, thereby providing a primary activation signal to the cells. The
invention employs a multimerization reagent that has immobilized thereon (bound thereto) a
first agent that provides a primary activation signal to the cells. This primary activation signal
may as such be sufficient to activate the cells to expand/proliferate. This first agent can either
be bound ibly or also irreversibly to the multimerization reagent. The multimerization
reagent may have immobilized thereon (bound thereto) also a second agent that stimulates an
accessory molecule on the surface of the cells. The second agent, when binding to the
accessory molecule on the surface on the surface of the cells, may y stimulate the
ted cells to expand. Also this second agent can either be bound reversibly or also
irreversibly to the multimerization reagent. The multimerization agent may either be
lized on a solid support or soluble. In one aspect, the method disclosed herein is a
serial expansion of a population of cells in which a complete population of lymphocytes is
stimulated/expanded, the reagents necessary for the expansion are then removed by
chromatography on a suitable stationary phase and the ed/stimulated cells are
optionally transfected with e.g. a T cell receptor or a chimeric antigen receptor (CAR) and
subjected to a second stimulation expansion with a different stimulatory molecule that binds
to the introduced T cell receptor or the chimeric antigen or. The invention also relates to
an apparatus for the expansion of the selected cell population.
BACKGROUND OF THE ION
The development of techniques for propagating T cell populations in vitro has
been crucial to many of the es in the understanding of T cell recognition of antigen and
T cell activation. The pment of culture methods for the generation of human antigen-
specific T cell clones has been useful in defining ns expressed by ens and tumors
that are recognized by T cells to establish methods of immunotherapy to treat a y of
human diseases. Antigen-specific T cells can be expanded in vitro for use in adoptive ar
immunotherapy or cancer therapy in which infusions of such T cells have been shown to have
anti-tumor reactivity in a tumor-bearing host. In addition, adoptive therapy has also
been used to treat viral infections in immunocompromised individuals.
A method of expanding human T cells in vitro in the e of exogenous
growth factor and accessory cells that has been established in the recent years is described in
US Patent 6,352,694 B1 and European Patent EP 0 700 430 B1. Disclosed in these patents is
an in vitro method for inducing a population of T cells to proliferate. The method comprises
contacting a tion of T cells with a solid phase surface having directly immobilized
thereon: (a) a first agent which provides a y activation signal to the T cells, thereby
activating the T cells; and (b) a second agent which stimulates an accessory molecule on the
surface of the T cells, y stimulating the activated T cells. The binding of the first agent
and the second agent to the T cells induces the T cells to proliferate/to expand. The preferred
first agent described in US Patent 6,352,694 B1 and European Patent EP 0 700 430 B1 is a
monoclonal anti-CD3 antibody which binds to the TCR/CD3 (TCR = T Cell Receptor)
complex and thereby stimulates the TCR/CD3 complex-associated signal in the T cells. The
preferred second agent according to these two patents is a monoclonal anti-CD28 antibody
which binds the accessory molecule CD28 that is present on T cells. Binding of this second
agent to the CD28 accessory molecule provides the necessary co-stimulus that is necessary for
expansion/proliferation of activated T cells. Meanwhile, Dynabeads® CD3/CD28 (Invitrogen)
are commercially available for T cell expansion. Dynabeads® 28 CTSTM are uniform,
4.5 um superparamagnetic, sterile, non-pyrogenic polystyrene beads coated with a mixture of
affinity purified monoclonal antibodies against the CD3 and CD28 cell surface molecules on
human T cells.
However, such magnetic beads are, for example, difficult to integrate into a
method to expand cells under conditions required for clinical trials or therapeutic purposes
since it has to be made sure that these magnetic beads are completely removed before
administering the expanded T cells to a patient. Thus, the present invention aims to provide an
alternative method for expanding cell populations such as regulatory T cells or central memory
T-cells for research, diagnostic and especially therapeutic es. Ideally, this new method
should also be compatible with integration into an automatized process which can be used for
rapid and easy expansion ofthe desired cells population for therapeutic applications.
This object is solved by the subject matter of the ndent claims, inter alia
the methods, kits, arrangements and apparatuses as recited in the ndent claims.
SUMMARY OF THE INVENTION
The t invention provides methods, kits, arrangements, and apparatus for the
in vitro expansion of a desired cell population, having a receptor molecule on its surface which
can provide upon binding of a le agent a primary activation signal to the population of
cells and thereby activating the population of cells for expansion (proliferation). Thus, the
methods of the invention are also used for inducing a population of cells to erate.
According to a first aspect, the invention provides an in vitro-method of expanding
a population of cells, sing ting a sample comprising the population of cells with a
erization reagent,
wherein the multimerization reagent has reversibly immobilized thereon (bound o)
a first agent that es a primary activation signal to the cells;
wherein the multimerisation reagent comprises at least one binding site Zl for the
reversible binding of the first agent,
wherein the first agent comprises at least one binding partner C1, n the binding
partner Cl is able of reversibly binding to the binding site 21 of the multimerization reagent,
wherein the first agent is bound to the multimerization reagent Via the reversible bond formed
between the binding partner Cl and the g site Zl and
n the first agent binds to a receptor molecule on the surface of the cells, thereby
providing a primary activation signal to the cells and thereby activating the cells.
According to a second aspect the invention provides an in vitro-method of
expanding a population of cells, comprising contacting a sample sing the population of
cells with a multimerization reagent,
wherein the multimerization reagent is in a soluble form and has immobilized thereon
(bound thereto) a first agent that provides a primary activation signal to the cells;
n the erisation reagent comprises at least one binding site Z1 for the binding
ofthe first agent,
wherein the first agent comprises at least one g partner Cl, wherein the binding
partner Cl is able of binding to the binding site Zl of the erization reagent, wherein the
first agent is bound to the multimerization reagent Via the bond formed between the binding
partner Cl and the binding site Zl , and
wherein the first agent binds to a receptor molecule on the e of the cells, thereby
providing a primary activation signal to the cells and thereby activating the cells.
According to a third aspect the invention provides a reagent kit for expanding a
population of cells, the kit comprising
(i) a multimerization reagent,
wherein the multimerisation reagent comprises at least one binding site Z for the reversible
binding of a first agent,
(ii) a first agent that binds to a receptor molecule on the surface of the cells, thereby
providing a primary activation signal to the cells and thereby ting the cells,
wherein the first agent comprises at least one binding partner Cl, n the binding
partner Cl is able of reversibly binding to a binding site Zl of the multimerization reagent,
wherein the first agent is bound to the multimerization reagent Via the reversible bond formed
between the binding partner Cl and the g site Zl and
(iii) a second agent that stimulates an accessory molecule on the surface of the cells,
wherein the second agent comprises a binding partner C2, wherein the binding partner
C2 is able of reversibly binding to a binding site Z2 of the multimerization t, wherein
the second agent is bound to the multimerization reagent via the bond formed between the
binding partner C2 and the binding site Z2,
wherein the second agent binds to the accessory molecule on the surface on the surface
ofthe cells, thereby stimulating the activated cells.
According to a fourth aspect the invention es a t kit for expanding a
population of cells, the kit comprising
(i) a erization reagent,
wherein the multimerisation reagent is in soluble form and comprises at least one binding
site Z for the reversible binding of a first agent,
(ii) a first agent that binds to a or molecule on the surface of the cells, thereby
providing a primary activation signal to the cells and thereby activating the cells,
wherein the first agent comprises at least one binding partner Cl, wherein the g
r C1 is able of g to a binding site Z1 of the multimerization reagent, wherein the
first agent is bound to the multimerization reagent Via the reversible bond formed between the
binding partner C1 and the binding site Z1.
According to a fifth aspect the ion provides an in vitro—method of serially
expanding a population of lymphocytes, wherein the population of cytes comprises T
cells, the method comprising
contacting a sample comprising the T cell comprising population of lymphocytes with a
multimerization reagent,
wherein the multimerization reagent is in a soluble form and has reversibly immobilized
thereon (i) a first agent that provides a primary activation signal to the T cells and (ii) a
second agent which stimulates an accessory molecule on the surface of the T cells,
wherein the multimerisation reagent comprises at least one binding site Z1 for the
reversible binding of the first agent,
wherein the first agent comprises at least one binding partner Cl, wherein the binding
partner C1 is able of reversibly binding to the binding site Z1 of the multimerization reagent,
wherein the first agent is bound to the multimerization reagent via the reversible bond formed
between the binding partner Cl and the g site Z1,
wherein the multimerisation reagent comprises at least one binding site Z2 for the
ible binding of the second agent,
wherein the second agent comprises at least one binding partner C2, wherein the binding
partner C2 is able of reversibly binding to the binding site Z2 of the multimerization reagent,
n the first agent is bound to the multimerization reagent via the reversible bond formed
between the binding partner C2 and the binding site Z2,
wherein the first agent binds to a receptor molecule on the surface of the T cells,
thereby providing a y activation signal to the cells and thereby ting the T cells,
wherein the second agent binds to the accessory molecule on the surface of the T cells,
thereby stimulating the activated cells, the first agent and the second agent thereby together
inducing the T cells to .
According to a sixth aspect the invention provides an arrangement of a bioreactor
and a stationary phase for chromatography,
wherein the bioreactor is suitable for the expansion of cells,
wherein the stationary phase is suitable for cell separation and removal of reagents, the
stationary phase being a gel filtration matrix and/or affinity chromatography matrix, wherein
the gel filtration and/or affinity chromatography matrix comprises an affinity reagent, wherein
the affinity t comprises a binding site 21 cally binding to a binding r Cl
comprised in a first agent and/or the affinity reagent comprises a binding site ZZ specifically
binding to a g partner C2 comprised in a second agent, thereby being suitable of
immobilizing on the stationary phase the first agent and/or the second agent, the first g
partner Cl and/or the free second binding partner C2,
wherein the bioreactor and the stationary phase are fluidly connected.
[0014] According to a seventh aspect the invention provides an apparatus for purification
and ion of a population of cells, the apparatus comprising at least one arrangement of a
bioreactor and a stationary phase for chromatography according to the sixth aspect.
According to an eight aspect, the invention provides a multimerization reagent
capable of expanding a population of cells,
wherein the erisation reagent is in soluble form and comprises at least one binding
site 21 for the reversible binding of a first agent that provides a primary activation signal
to the cells,
wherein the multimerization reagent has reversibly immobilized thereon (bound thereto) said
first agent that es a primary activation signal to the cells;
wherein the first agent comprises at least one g partner Cl, wherein the binding partner
C1 is able of reversibly binding to the at least one binding site Zl of the multimerization
reagent,
wherein the first agent is bound to the erization t via the reversible bond formed
between the binding partner Cl and the binding site Z1,
ing to a ninth aspect, the invention provides a composition capable of
expanding a population of cells, the composition comprising
(i) a first multimerization reagent,
wherein the first multimerisation reagent is in soluble form and comprises at least one
binding site Zl for the reversible binding of a first agent that provides a primary
activation signal to the cells,
wherein the first multimerization reagent has reversibly immobilized n (bound
thereto) said first agent that provides a primary activation signal to the cells;
wherein the first agent comprises at least one binding r Cl, wherein the binding
partner Cl is able of reversibly g to the at least one binding site Zl of the
multimerization reagent, wherein the first agent is bound to the multimerization reagent
via the reversible bond formed n the binding partner C1 and the binding site Zl,
(ii) a second erization reagent,
wherein the second multimerization reagent is in soluble form and comprises at least one
binding site 22 for the reversible binding of a second agent that stimulates an accessory
le on the surface of the cells,
wherein the multimerization reagent has reversibly immobilized thereon (bound
thereto) said second agent that stimulates an accessory molecule on the surface of the
cells,
n the second agent comprises a binding partner C2, wherein the binding partner
C2 is able of binding to the at least one binding site 22 of the multimerization reagent,
wherein the second agent is bound to the multimerization reagent via the bond formed
between the binding partner C2 and the binding site 22.
DESCRIPTION OF THE DRAWINGS
The invention will be better tood with reference to the detailed description
when considered in conjunction with the non-limiting examples and the accompanying
drawings. The figures illustrate embodiments of methods ofthe invention. Without wishing to
be bound by theory, the figures include conclusions with regard to the underlying expansion
mechanism. The conclusions are given for illustrative purposes only and merely serve in
allowing a visualization of the ion method is achievable on a molecular level.
Figure 1 depicts an embodiment of an in vitro—method of expanding of
expanding a population of cells that has a cell surface receptor the binding of which by a first
agent can provide an activation signal for the cells to expand.
As shown in Fig. 1a a sample that comprises the population of cells (2) that carry
a surface receptor molecule (30) is contacted with a multimerization reagent (4). The
population of cells (2) is in mixture with other cell tions (22) that lack the e
receptor molecule (30). The multimerization reagent (4) has reversibly lized n
(bound thereto) a first agent (6) that provides a primary activation signal to the cells. The
multimerization t (4) comprises at least one binding site Z1 (42) for the reversible
binding of the first agent (6) and the first agent (6) comprises at least one binding partner C1
(6a), n the g partner C1 (6a) is able of reversibly binding to the binding site Z1
(44) of the multimerization t. Thus, for immobilization, the first agent (6) is bound to
the erization reagent (4) via the reversible bond formed between the binding partner Cl
(6a) and the binding site Z1 (42). In the example shown in Fig. 1 the multimerization reagent
(4) has a second binding site Z2 (44) which is not used in this example. The multimerization
reagent (4) is itself immobilized on a solid support (10) such as a magnetic bead, a polymeric
bead of a surface of a cell culture plate or reactor. The population of cells (2) can, for example
be, a lymphocyte cell population such as a population of B cells that can be activated via the
CD40 receptor (see, for example, Carpenter et al, Journal of Translational ne 2009,
7:93 “Activation of human B cells by the agonist CD40 dy CP-870,893 and
augmentation with simultaneous toll-like receptor 9 stimulation). In this case, the cell surface
molecule (30) is CD40 and the first reagent (6) can be any CD40 binding molecule that
provides the desired activation , for example, the monoclonal antibody ,893 or an
antibody binding nt thereof such an a monovalent Fab fragment. The binding partner
C1 of the first agent (6) may, for example, be any affinity peptide that is {used or conjugated
to, for example, the C-terminus of one the two polypeptide chains (heavy or light chain) of the
antibody molecule. The binding partner C1 (6a) may, for example, be a streptavidin-binding
peptide such as the peptide Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 01), also known
as the “Strep-tag®”) that is described in US patent 5,506,121, for example, or streptavidin
binding peptides having a sequential arrangement of two or more individual binding modules
as described in International Patent Publication WO 02/077018 or US patent 7,981,632. When
using a streptavidin binding peptide as binding partner C1, the multimerization reagent (4) be
any streptavidin mutein to which the streptavidin peptide (= first binding r C1 (6a))
reversibly binds via its (biotin) binding sites Z1 (42) schematically shown in Fig. 1. Such a
multimerization reagent may be a streptavidin mutein (analog) that comprises the amino acid
sequence Va144"I"hr45-Ala46-Arg47 (SEQ ID NO: 02) at ce positions 44 to 47 of wild
type streptavidin or a streptavidin mutein (analog) that comprises the amino acid ce
lle44—Gly45—Ala46—Arg47 (SEQ ID NO: 03) at sequence positions 44 to 47 of wild type
streptavidin, both of which are described in US patent 6,103,493, for example, and are
cially available under the trademark Tactin®. In the Example of Fig. l, the
multimerization reagent (4) might further include multimeric calmodulin or glutathione-S-
transferase, both of which form reversible bonds with calmodulin binding peptides or
glutathione. Thus, the binding site Z2 (44) can be formed by calmodulin or glutathione-S-
transferase. Such a protein conjugate of for e, calmodulin with a streptavidin mutein
can be made by standard protein chemistry, for example, by using bifunctional linkers.
As shown in Fig. 1b, after contacting the cell population (2) with the
multimerisation reagent (4) and usually incubating the cell tion with the erization
reagent (4), the population of cells (2) forms complexes/is bound to the multimerization agent
via the first agent (6). The first agent binds specifically to the cell surface receptor molecule
such as CD40 in this e and provides the activation signal for cell expansion, of for
example B cells. The other cell populations (22) contained in the initial sample that lack the
specific cell surface molecule (30) do not bind to the multimerization reagent. In this respect, it
is noted that the cell population (2) usually has multiple copies of the cell surface molecule
(30) on its surface and binding of these multiple copies is typically needed for activation.
Thus, the multimerization agent (4) provide typically more than one binding site Z1 so that
le first agents (6) can be reversibly bound to achieve “multimerization” of the first
agent, meaning to present the first agent in a sufficient density to the population of cells (2)
(not shown in the scheme of Fig.1). In this respect, it is noted that a erization agent as
used herein can as such have le binding sites Z1, for example, a streptavidin mutein
(being a homo-tetramer) in its native state has four such binding sites Z1. It is however also
possible that the multimerization reagent is based on a compound that has as such only one
binding site Z1 for the reversible binding of a binding partner C1. Such an example is
multimeric calmodulin. Calmodulin as such has only one g site for calmodulin binding
peptides. However, ulin can be biotinylated and then reacted with streptavidin-
oligomers (see also below), thereby providing a multimerization reagent in which multiple
calmodulin molecules are ted in high density on a “scaffold”, thereby providing
multimeric calmodulin.
As shown in Fig.1c, after tion (which is usually carried out over a period
of time suitable to achieve expansion of the desired cell population) the binding between the
binding partner Cl (6a) of the first agent (6) and the binding site 21 of the multimerization
reagent (4) is disrupted by disrupting the respective reversible bond. The disruption may be
achieved by adding a competitor to the incubation/reaction mixture ning the population
of cells (2) being bound to the multimerization reagent. For competitive disruption (which can
be understood as being a competitive elution) of the reversible bond between the binding
partner Cl (6a) of the first agent and the binding site Z1 (22) of the multimerization reagent,
the incubation mixture/population of cells can be contacted with a free first binding partner Cl
(20) or an analog of said first binding partner C that is capable of disrupting the bond between
the first binding partner Cl (6a) and the binding site Z1 (22). In the example of the g
partner Cl being a streptavidin binding peptide that binds to biotin binding site of streptavidin,
the first free partner Cl (20) may be the ponding fiee streptavidin binding peptide or an
analogue that binds competitively. Such an analogue can, for example, be biotin or a biotin
derivate such as desthiobiotin.
As shown in Fig. 1d, addition ofthe first free partner (20) or the analogue f
results in displacement of the g partner Cl (6a) from the erization reagent (4) and
thus, since the binding r Cl is comprised in the first agent (6), displacement of the first
agent (6) from the multimerization reagent (4). This displacement of the first agent (6) in turn
results in a dissociation of the first agent (6) from the cell surface receptor (30), in particular if
the binding y of the bond between the first agent and the cell surface or (30) has a
dissociation constant (Kd) in the range of 10'2 M to 10'13 M and is thus also ible. Due to
this dissociation, the stimulation of the cell population (2) is also terminated. Thus, the present
invention provides the advantage that the time period of the stimulation or expansion of the
cell population can be exactly controlled and thus also the fimctional status of the cell
population can be closely controlled. In this context, it is noted that the binding affinity of
antibody molecules towards their antigen, including for e, a cell surface receptor
molecule such as CD40 in this Example, is usually in the affinity range of the Kd of 10‘7 M to
'13 M. Thus, tional monoclonal dies can be used as first agent (and also of
course second agent as explained below) in the present invention. In order to avoid any
unwanted avidity s that lead to a stronger binding, monoclonal dies can also be
used in form of their monovalent antibody fragments such as agments or single chain Fv
nts.
In addition, due to the dissociation of the first agent from the cell surface
molecule (30), the present invention has the added advantage that the stimulated cell
population is free of stimulating agents at the end of the stimulation period and that all other
reagents used in the method, namely the first agent (6) as well as the free first partner (20) of
the binding partner C1 or the analogue thereof can be easily removed from the stimulated cell
population (2) via a “removal cartridge” described in International patent application WC
2013/124474 while the multimerization reagent (4) being immobilized on a solid support such
as a bioreactor surface or a magnetic bead is being held back. Thus, reverting to the l of
the free agent (6) and the free first partner (20), in accordance with the description of the
“removal cartridge” in WC 2013/124474 (see with reference to Fig. 4 thereof, for example),
the elution sample obtained in Fig. 1d here can be loaded onto the second chromatography
column ofWC 2013/124474. This chromatography column has a suitable stationary phase that
is both an affinity chromatography matrix and, at the same time, can act as gel permeation
matrix. This affinity chromatography matrix has an affinity reagent immobilized n. The
affinity reagent may, in the case of the current e, for instance, be streptavidin, a
avidin mutein, avidin, an avidin mutein or a mixture thereof. The first agent (6), the free
first r (20) of the binding partner C1 (which is also called “competition reagent” herein)
bind to the affinity reagent, y being immobilized on the chromatography matrix. As a
result the elution sample containing the ed and expanded cell population (2) is being
depleted of the first agent (6) and the competition reagent (20). The expanded cell population
(2), being freed of any reactants, is now in a condition for further use, for example, for
diagnostic applications (for example, further FACSTM sorting) or for any cell based therapeutic
application.
Fig.2 shows a further embodiment of an ion method of the invention. As
shown in Fig. 2a a sample comprises a population of cells (2) that carry two c cell
surface molecules (30) and (32). The cell e molecule (30) is involved in a primary
activation signal to the cell population, while the cell surface molecule (32) is an accessory
molecule on the cell surface that is involved in providing a stimulus to the cells. The
population of cells may, for example, be a T cell population in which the cell surface molecule
(30) is a TClVCD3 complex and the cell surface le (32) is the accessory molecule
CD28. Binding of both the TCWCD3 x as the primary activation signal and CD28 as
co-stimulant are necessary for expansion/proliferation ofT cells. The population of T cells (2)
is in mixture with other cell populations (22) that lack the surface receptor molecules (30) and
(32). Also in this embodiment, the cell population (2) is contacted with a erization
reagent (4). The multimerization reagent (4) has reversibly immobilized thereon (bound
thereto) a first agent (6) that provides a y activation signal to the cells. In on, the
multimerization agent has reversibly immobilized thereon (bound thereto) a second agent (8)
that stimulates CD28 as accessory molecule on the surface of the cells.
The multimerization reagent (4) comprises at least one binding site Z1 (42) for
the reversible g of the first agent (6) and the first agent (6) comprises at least one
binding partner Cl (6a), wherein the binding partner Cl (6a) is able of reversibly binding to
the binding site Z1 (44) of the multimerization reagent. Thus, for lization, the first
agent (6) is bound to the multimerization reagent (4) via the ible bond formed between
the binding partner Cl (6a) and the binding site Z1 (42). In addition, in the Example illustrated
in Fig. 2, the second agent (8) comprises a binding partner C2 (8a), wherein the binding
partner C2 is able of being reversibly bound to a binding site Z2 (44) of the multimerization
reagent (4). The second agent (8) is bound to the multimerization reagent (4) via the reversible
bond formed between the binding partner C2 (8a) and the binding site Z2 (44). In this
Example, the first agent (6) might be a monoclonal anti-CD3-antibody or an antigen binding
fragment f such as a Fab fragment. The second agent (8) might be a monoclonal anti-
CD28 antibody or an antigen binding fragment thereof such as Fab nt. The first binding
partner (6a) might be a streptavidin binding peptide (6a) that is fused or conjugated to the anti-
CD3 dy or the anti-CD3 antibody fragment. The second binding r (8a) might be
calmodulin binding peptide that is also conjugated or fiised to the CD28 antibody or the CD28
binding antibody fragment. In this context, it is noted that monoclonal antibodies against, for
example, CD3 or CD28 are well-known (see, for example, US Patent 6,352,694 B or European
Patent EP 0 700 430 B1 discussed above) and are commercially available from us
suppliers such as Santa Cruz Biotechnology (Santa Cruz, CA, USA), Life Technologies,
(Carlsbad, CA, USA), BD Biosciences (San Jose, CA, USA), Biolegend (San Diego, CA,
USA) or Miltenyi Biotec (Bergisch Gladbach, Germany) to name only a few. Accordingly,
such monoclonal antibodies can be used as first and second agent and can, for example, be
chemically coupled gated) with a g partner C1 or C2. Alternatively, it is also
possible to either clone the genes of the variable domains from the hydridoma cell line or use
an antibody of which the amino acid ce is known and produce a tive antibody
nt such as a Fab fragment or a FV recombinantly. When using such an approach as
described herein in the Example section for both the hybridoma cell line OKT3 (ATCC® CRL-
8001TM, described in US Patent 4,361,549) that produces a monoclonal anti—CD3 antibody) and
the anti-CD28 antibody 28.3 described by Vanhove et a1, BLOOD, 15 July 2003, Vol. 102,
No. 2, pages 564-570 and GenBank accession number 74.1, the binding partners C1
and C2 are conveniently provided by the respective expression vector used for the recombinant
production so that the antibody fragment carries the binding partner C1 or C2 as a fusion
peptide as the C—terminus of either the light or the heavy chain (In this context, the amino acid
sequence of the variable domain of the heavy chain and of the variable domain of the light
chain of the antibody OKT3 that are described in Arakawa et al J. Biochem. 120, 657-662
(1996) are shown for illustration purposes as SEQ ID NOS 17 and 18 and in the accompanying
Sequence Listings, While the amino acid sequence of the variable domain of the anti-CD28
antibody 28.3 described by Vanhove et a1, supra, is shown as SEQ ID NOS 19 (VH) and 20
(VL) in the accompanying Sequence Listings). Also this methodology of cloning the variable
domains of an antibody molecule and inantly producing a respective antibody fragment
is well known to the person skilled in the art, see for example, Skerra, A. (1994) A general
vector, pASK84, for g, bacterial production, and single-step purification of antibody Fab
fragments. Gene 141, 79-84, or Skerra, A. (1993) Bacterial expression of immunoglobulin
fragments. Curr Opin Immunol. 5, 256-562). Finally, it is also possible to generate antibody
molecules of cial binding molecules with antibody like properties against a given target
such as CD3 or CD28 as in the Example of Fig. 2 by well—known evolutive methods such as
phage y wed, e.g., in Kay, B.K. et a1. (1996) Phage Display of Peptides and
Proteins — A tory Manual, 1St Ed., Academic Press, New York NY; Lowman, H.B.
(1997) Anna. Rev. s. Biomol. Stract. 26, 401—424, or Rodi, DI, and Makowski, L.
(1999) Curr. Opin. Biotechnol. 10, 87—93), ribosome y (reviewed in Amstutz, P. et a1.
(2001) Curr. Opin. Biotechnol. 12, 400-405) or mRNA display as reported in Wilson, D.S. et
al. (2001) Proc. Natl. Acad. Sci. USA 98, 3750-3755.
In the case of the Example shown in Fig. 2, the erization reagent (4) has
two different g sites Z1 (42) and Z2 (44). With the binding partner C1 (6a) being a
streptavidin binding peptide, the binding site Z1 (42) of the multimerization reagent (4) is
ed by a suitable streptavidin mutein to which the streptavidin peptide (6a) reversibly
binds. Since the binding C2 is a calmodulin g peptide, the binding site Z2 (44) of the
multimerization t (4) is provided by multimeric calmodulin. The multimerization
reagent (4) can be a single molecule, for example a conjugate of multimeric calmodulin with
streptavidin (this alternative would be usually used in case of a soluble erization) or can
also consist of two ndent molecules. The latter option is preferred when the
multimerization reagent (44) is immobilized on a solid support as shown in Fig.2 In this case,
a mixture of a streptavidin mutein and calmodulin can be coated (immobilized) on the solid
support, for example, in a 1:1 molar ratio with respect to the binding sites Z1 and Z2. In this
context, it is noted that, due to the immobilisation of calmodulin on the surface of the solid
support, there is no need to prepare multimeric calmodulin as explained above but
immobilization of the calmodulin on the surface is sufficient to present ulin (that, as
mentioned above, has only a single binding site for calmodulin binding peptides, in a
sufficiently high density to ensure binding of the cell population (2). For example, in this case,
a bivalent antibody fragment that has two binding sites against CD28 or an intact antibody that
has per se two identical binding sites could be used as second reagent (8).
[0027] As shown in Fig. 2b, after contacting the T cell population (2) with the
multimerisation reagent (4) and usually ting the cell population with the multimerization
reagent (4), the population of T cells (2) forms xes/is bound to the multimerization
agent via the first agent (6) and the second agent (8). The first agent (6) and the second agent
(8) bind specifically to the 3 complex and the ory molecule CD28, thereby
inducing the T cells to proliferate/expand.
As shown in Fig. 2c, after incubation (which is usually carried out over a period
of time suitable to achieve expansion of the desired cell population) the binding between the
binding partner Cl (6a) of the first agent (6) and the binding site Zl of the erization
reagent (4) is disrupted by disrupting the respective reversible bond. se, the binding
between the g partner C2 (8a) of the second agent (8) and the binding site Z2 of the
multimerization reagent (4) is disrupted by disrupting the respective reversible bond. The
reversible bond between the binding partner Cl (6a) of the first agent (6) and the binding site
Zl can be disrupted by biotin (which acts as an ue (20) of the free first partner) while
the reversible bond between the binding partner C2 (8a) of the first agent (8) and the binding
site Z2 can be disrupted by the addition of a metal chelator (calcium chelator) such as EDTA
or EGTA (that acts an analogue (20) of the free second r) since the binding of
calmodulin to calmodulin binding peptides is calcium ion (Ca2+) dependent). This of course
means that the contacting of the cell tion (2) is carried out in a Ca2+ containing buffer.
As shown in Fig. 2d, addition of the analogue (20) of the first free partner and
the second free partner, respectively results in displacement of the binding rs C1 (6a)
and C2 (8a) from the multimerization reagent (4) and thus in displacement of the first agent (6)
and the second agent (8) from the multimerization reagent (4). This displacement of the first
agent (6) and second agent (8) in turn results in a dissociation of the first agent (6) and the
second agent (8) from the TCR/CD3 complex and the accessory le CD28, thereby
terminating the stimulation/expansion of the cell population (2). Thus, as said above, the
present invention provides the age that the time period of the stimulation or expansion
of a T cell population can be exactly controlled and therefore also the fimctional status of the
population of T cells can be closely controlled. After the elution of the cells as illustrated in
Fig. 1d, the first agent (6), the second reagent (8) as well as the analogue (20) of free first
partner of the binding partner Cl and the second free partner of the binding partner C2 can be
easily removed from the stimulated cell population (2) via a “removal cartridge” described in
International patent application . In addition, and importantly, in case the
initial sample was a population of lymphocytes, for example, in form of PMBCS obtained from
a Ficoll gradient, the T cell population (2) is now available for serial expansion as defined
here. Since the expanded cell population (e.g. by an initial stimulation via CD3/CD28) can be
transfected during expansion e.g. with a T cell or (TCR) or a ic antigen receptor
(CAR, also known as ial T cell receptor), the genetically modified cells can then be
ted from the initial stimulus and subsequently be ated with a second type of
stimulus e.g. via the de novo introduced or. These second stimuli may comprise an
antigenic stimulus in form of a peptide/MHC molecule, the cognate (cross-linking) ligand of
the genetically introduced receptor (e.g. natural ligand of 21 CAR) or any ligand (such as an
antibody) that directly binds within the ork of the new receptor (e.g. by recognizing
constant regions within the receptor). Thus, the T cell population obtained from this serial
expansion can be used for adoptive cell transfer.
Fig. 3 shows a further embodiment of an expansion method of the invention. Also
the sample used in this Example comprises a population of T cells (2) that carry two c
cell surface molecules (30) and (32), with the cell surface molecule (30) being a TCR/CD3
complex and the cell surface molecule (32) being the accessory molecule CD28. In Fig. 3a the
population of T cells (2) is shown after being contacted with a multimerization reagent (4).
Also in this Example, the multimerization t (4) has reversibly immobilized thereon
(bound thereto) as first agent (6) an anti-CD3 antibody or an antigen g fragment thereof
that provides a primary activation signal to the T cells and as second agent (8) an anti-CD28
antibody or an antigen binding fragment thereof that stimulates CD28 as ory molecule.
The multimerization reagent (4) shown in the Example of Fig. 3 comprises only
one type binding site Z1 (42) for the reversible binding of both the first agent (6) and the
second agent (8). Both the first agent (6) and the second agent (8) comprise at least one
binding partner Cl (6a, 8a), wherein both the binding r Cl (6a) and the binding partner
(8a) are able of reversibly binding to the binding site Z1 (44) of the multimerization reagent.
Thus, for immobilization, the first agent (6) and the second agent (8), respectively are bound to
the multimerization reagent (4) via the reversible bond formed between the binding partner C1
(6a) and the binding partner C2 and the binding site Z1 (42). The binding partners Cl and C2
can either be different or identical. For example, the g r C1 can be a streptavidin
binding peptide of the sequences r-His-Pro-Gln-Phe—Glu-Lys ((SEQ ID NO: 01), the
“Strep-tag®”) while the binding partner C2 can be the streptavidin binding peptide of the
sequence Trp-Ser-His-Pro-Gln-Phe-Glu-Lys-(GlyGlyGlySer)3-Trp-Ser-His-Pro-Gln-Phe-Glu-
Lys ((SEQ ID NO: 04), also known as “di—tag3”)) or of the sequence Trp-Ser-His-Pro-Gln—
Phe-Glu-Lys-(GlyGlyGlySer)2-Trp-Ser—His—Pro-Gln-Phe-Glu-Lys ((SEQ ID NO: 05), also
known as “the di-tag2”), bed by Junttila et al., Proteomics 5 (2005), 1199—1203 or US
Patent 7,981,632). All these streptavidin binding peptides bind to the same binding site,
namely the biotin binding site of streptavidin. If one or more of such streptavidin binding
es is used as g partners Cl and C2, the multimerization reagent (4) is a
streptavidin mutein. As shown in Fig. 3, a soluble multimerization reagent (4) is used. In the
case of a streptavidin mutein, this soluble multimerization reagent may, for example, be an
oligomer or a polymer of streptavidin or avidin or of any mutein g) of streptavidin or
avidin. The oligomer may comprise three or more monomers of streptavidin, avidin or a
mutein therof. The oligomer or polymer may be crosslinked by a polysaccharide. Such
oligomers or polymers of streptavidin or of avidin or of muteins of streptavidin or of avidin
can in a first step be prepared by the introduction of carboxyl residues into a polysaccharide, e.
g. n, essentially as described in hi, A., Takahashi, T., Yamaguchi, T., Kitamura,
K., Takakura, Y., Hashida, M. & , H. (1992). Preparation and properties of the
immunoconjugate composed of anti-human colon cancer monoclonal antibody and mitomycin
C dextran conjugate. Bioconjugate Chemistry 3,132-137”. In a second step, streptavidin or
avidin or muteins thereof are coupled Via primary amino groups of internal lysine residue
and/or the free inus to the carboxyl groups in the dextran backbone using conventional
carbodiimide chemistry. Alternatively, cross-linked oligomers or polymers of avidin or
avidin or of any muten of streptavidin or avidin may also be obtained by crosslinking via
bifunctional linkers such as glutardialdehyde or by other methods described in the literature.
Using as binding partners Cl and C2, moieties that bind to the same binding site
(42) of the multimerization agent has the advantage that, as shown in Fig. 3b, the same free
partner (of the first binding partner C1 and also of the second binding partner C2) or ue
thereof can be used to ate the expansion of the population of T cells (2) and to release
this population of T cells (2) from the multimerization agent. In the Example of Fig. 3, an
analogue of the first and second partner Cl and C2 such as biotin or a biotin derivate
(iminobiotin or obiotin) can be iently used for the termination of the expansion
and the n of the tion of T cells (2).
[0033] As Shown in Fig. 30, after the n of the cells as illustrated in Fig. 1d, the first
agent (6), the second reagent (8) as well as biotin as the analogue (20) of free first r of
the g partner Cl and the second free partner of the binding partner C2 can be easily
removed from the stimulated cell population (2) via a “removal cartridge” described in
International patent application . In addition, the embodiment of using a
soluble multimerization reagent (4) has the further advantage of being able to avoid any solid
support such as magnetic beads. This means there is no risk of contamination of the activated
T cells by such magnetic beads. This also means that a process that is compliant with GMP
standards can be much easier established compared to the known method such as the use of
Dynabeads® in which additional measures have to be taken to ensure that the final expanded T
cell population is free of magnetic beads. Furthermore, the use of a soluble multimerisation
agent makes it much easier to remove the same from the activated cell population (T cells, B
cells or also natural killer cells) since the cells can be simple sedimented by centrifiJgation and
the supernatant ing the soluble multimerization agent can be discarded. Alternatively,
the soluble multimerization agent can be removed from the expanded cell population in a gel
permeations matrix of the removal cartridge of International patent application WO
2013/124474. Since no solid phase (e.g. magnetic beads) are present, the present invention
also provides for an automated closed system for expansion ofthe cells that can be integrated
into known cell expansion systems such as the Xuri Cell Expansion System W25 and WAVE
Bioreactor 2/10 System, available from GE care (Little Chalfont, Buckinghamshire,
United Kingdom) or the Quantum® Cell Expansion System, available from TerumoBCT Inc.
(Lakewood, CO, USA).
Fig. 4 shows the results of an experiment in which CD3+ T responder cells were
proliferated after being stimulated in vitro with (xCD3 and (xCD28 Fab fragments that were
reversibly immobilized on beads coated with the streptavidin mutein tactin®. Fig. 4A in
a histogram g size-distribution (forward scatter) of stimulated cells, Fig. 4B depicts
histograms representing the degree of eration according to the number of cells per cell
division that are indicated on top of Fig. 4B (0 represents undivided cells; 5 ents cells
that have gone through at least 5 divisions), and Fig. 4C shows a picture of the culture dish
after 4 days of ation.
Fig. 5 shows the results of the differential intracellular calcium mobilization in
Jurkat cells that are either labelled with the (1CD3 antibody OKT3 or with Fab fragments of
OKT3 being multimerized with Strep—tactin® (also referred to as Fab multimers herein). Fig.
5A: Jurkat cells were loaded with the calcium-sensitive dye Indo-l-AM and calcium release
was red by injection of either (xCD3 mAb (black squares) or OLCD3 OKT3 Fab multimers
(derived from the parental cell line OKT3) with or without prior D—biotin disruption (dark grey
triangles and light grey circles respectively) compared to injection of PBS (inverted white
triangles). Application of ionomycine served as positive l. Time-resolved changes in
intracellular Ca2+ concentration were monitored by flow-cytometry based on the change in
FL6/FL7 ratio. Fig. 5B: Indo-l-AM-labeled Jurkat cells were activated by different uCD3
stimuli as described in Fig 4a; OKT3: upper graph and uCD3 Fab-multimer: middle graph)
followed by uent s) D-biotin mediated disruption of uCD3 Fab-multimer
signaling. Injection of PBS (lower graph) and cine served as negative or positive
control. Data are representative of three different experiments.
Fig. 6 shows the result of the reversible staining of cells by anti CD3 OKT3 Fab-
multimers. Freshly isolated PBMCs were stained with either a monoclonal antibody (left dot
plot, parental clone for the Fab—multimers) or cognate PE-labeled Fab-multimers and analyzed
either before (second left ) or after treatment with D-biotin (middle ).
Remaining Fab monomers were then detected after subsequent washing steps using fresh PE-
labeled Tactin® (second right column). Secondary Fab-multimer staining of reversibly
stained cells served as control (right column). Only live (PInegative) cells are shown. Numbers in
dot plots indicate the percentage of cells within gates.
Fig. 7 shows the isolation of cells by reversible binding of anti-CD28 Fab
fragments multimerized with Strep-Tactin® labeled with phycoerythrine as a fluorescent label.
CD28+ cells were selected/isolation by Fab-multimer magnetic cell selection from y
isolated PMBCs as described in International Patent Application W02013/011011. Before
selection cells were l stained with either the cognate fluorescent aCD28-multimers (left
dot plot) or with an antibody ed against the globulin kappa light chain (second
left dot plot, (x—Ig kappa mAb). After selection, cells were treated with D-biotin and
subsequently washed to remove ic beads and nomers. Liberated CD28+ cells
were subsequently tained either with CD28 Fab-multimers (second right dot plot) or with
the (x-Ig kappa mAb (right dot plot) to detect potentially remaining Fab-monomers. Only live
(PInegafive) CD3+ cells are shown. Numbers in dot plots indicate the percentage of cells within
gates.
Fig. 8 shows the results of an ment in which CD3+ T responder cells were
proliferated after being stimulated in vitro with reversible (XCD3/0LCD28 Fab fragments that
were reversibly immobilized on soluble oligomeric Strep-tactin® acting a e
multimerization reagent. For the experiments the results of which are shown in Fig. 8,
300.000 CD3+ responder T cells (Tresp) were labeled with 2uM Carboxyfluorescein
succinimidyl ester (CFSE) and stimulated with varying amounts of a ation of soluble
Streptactin oligomers on which a combination of (xCD3 Fab fragment and (xCD28 Fab both
carrying a Strep-tag as streptavidin binding peptide at the heavy chain were immobilized.
(“1x” corresponds to 3ug multimerized Strep-tactin functionalized with 0.5ug (xCD3— and
0.5 ug 0LCD28 Fab; numbers indicate fold amount of “lx”). Tresp cells either left unstimulated
or were stimulated with blank tactin multimers (no Fab) served as ve control.
Tresp cells were seeded in duplicates in 48-well plates along with 300.000 CD3 negative
autologous feeder cells (irradiated with 30Gy) in lml cell culture medium supplemented with
20U/ml interleukin 2 (IL-2). Cells were incubated at 37°C without media exchange and
proliferation was analyzed according to CFSE dilution after 5 days by FACS analysis (Fig.
8B). Fig. 8A shows size distribution of cells after 5 days in culture. rams show live
CD3+ cells, while Fig. 8C shows cells after culture that were liberated by stimulation reagents
after d with lmM D-biotin and washed. The dissociation and removal of monomeric Fab
fragments was analyzed by restaining with Strep-Tactin® d with phycoerythrine (STPE
) as a fluorescent label and a representative histogram is shown. Fig. 8D shows the absolute
number of live (trypan blue negative) cells after 5 days was counted using a Neubauer
counting chamber and d against the respective stimulation condition. Median cell
numbers are shown in Fig. 8D; error bars indicate standard deviation (SD). Fig. 8E shows a
picture of the culture dish after 5 days of stimulation.
Fig. 9 depicts an illustration of the serial expansion method of the present
invention (Fig. 921) while Fig. 9b briefly describes some features and advantages of the serial
expansion.
Fig. 10 shows an arrangement of the invention that can be used er with the
expansion methods of the invention. This arrangement (100) includes a bioreactor (50), a first
“removal cartridge” (70) and a second “removal cartridge” (90). The ctor (50) is fluidly
connected to the first removable cartridge (70), and the first removal cartridge is fluidly
connected to the second removal cartridge (90). This arrangement (100) can be part of a device
for automated cell expansion and purification as described here.
In the bioreactor (50) an expansion method as described herein is carried out, for
example an ion method illustrated in Fig. 3 that makes use of a soluble multimerization
reagent. In this case, after termination of the activation/expansion of the cell population (2) by
addition of a competitor (20) (free partner of the binding partner C1 or an analogue thereof)
the reaction mixtures that is released from the bioreactor contains the expanded population of
cells (2), the first agent (6), the second agent (8) as well as the soluble multimerization reagent
(4). In this example, the first agent (6) is a CD3 g dy fragment that includes a
streptavidin binding peptide as binding r C1, the second agent (8) is a CD28 binding
antibody fragment that includes a streptavidin binding peptide as binding partner C1 and the
competitor (20) (free analogue of the binding partner Cl) is . This reaction mixture is
applied on the first removal cartridge (70). This first removal cartridge (70) is a removal
cartridge as described in International patent application WC 2013/124474 that includes a
chromatography column with a suitable stationary phase. The stationary phase can serve both
an affinity chromatography matrix and, at the same time, can act as gel permeation matrix.
This affinity chromatography matrix has an affinity reagent immobilized thereon. The affinity
reagent may, in the case of the current Example, for ce, be streptavidin, a streptavidin
mutein, avidin, an avidin mutein or a mixture thereof. Thus, the first agent (6) and the second
agent (8) bind to the affinity reagent via their streptavidin binding peptide. Also biotin as the
competitor (20) binds to the affinity reagent. Thus, these three reagents are all being
immobilized on the chromatography matrix of the first removal cartridge while the expanded
cell population (2) and the soluble multimerization t (4) pass through the stationary
phase. This “flow through” is then d onto the second removal cartridge (90). Also this
second removal cartridge (90) ses a nary phase. This stationary phase comprises a
second affinity reagent thereon which is able to bind to the binding site Z1 (42) of the
multimerization reagent (4). This affinity reagent may for example be biotin that is ntly
bound to the stationary phase. Such a nary phase may, for e, be d-biotin
SepharoseTM obtainable from Affiland S.A. (Ans-Liege, m). Thus, the soluble
multimerization reagent (4) will be bound (retained) on the stationary phase of the second
removal cartridge (90) while the expanded population of cells (2) passes through the stationary
phase and is being freed of any reactants. The population of cells (2) is now in a condition for
any further use, for example, for diagnostic applications (for example, further FACSTM
sorting) or for any cell based therapeutic application. It is noted here that it is of course also
possible to change the order of the first “removal cartridge” (70) and the second “removal
cartridge” (90) in an arrangement (100), such that bioreactor (50) is (directly) fluidly
connected to the second removable cartridge (90), and the first removal cartridge (70) is
arranged after and fluidly connected to the second removal cartridge (90). In this arrangement
the erization reagent (4) will first be removed from the population of cells (2) and
subsequently the first agent (6), the second (8) and e.g. the competitor (20) are removed. Such
an arrangement is also encompassed in the present invention and can also be part of a device
for automated cell expansion and purification as described here.
[0042] Fig. 11 shows a r embodiment of an arrangement of the invention that can
be used together with the expansion methods of the invention. This arrangement (110) includes
a bioreactor (50), a first “removal cartridge” (70) and a second “removal cartridge” (90). The
bioreactor (50) is fluidly connected to the first removable dge (70), and the first l
cartridge is fluidly connected to the second removal cartridge (90). In addition, the second
removal cartridge (110) is fluidly connected to the bioreactor (50). This arrangement (110) can
also be part of a device for automated cell ion and purification as described here. When
used, for example, together with an expansion method that employs a e multimerization
t (4), a purified expanded tion of cells (2) is ed as eluate of the second
removal dge (90). Since the removal cartridge (90) is fluidly connected to the bioreactor
(50), the population of cells (2) can be transferred back into the bioreactor (50), for example,
to serial clonal expansion as described here, by transfecting the population of cells, for
example, with the gene of an T cell receptor and subsequent further (second) expansion using
an expansion method of the ion.
Fig. 12 shows a fiirther embodiment of an arrangement of the invention that can
be used together with the expansion methods of the invention. This arrangement (120) includes
a bioreactor (50), a first “removal cartridge” (70) and a second “removal cartridge” (90). The
ctor (50) is fluidly connected to the first removable cartridge (70), and the first removal
cartridge is fluidly connected to the second removal dge (90). Similar to the embodiment
shown in Fig. 11, the second removal cartridge (110) is fluidly ted to the bioreactor
(50). However, a “selection cartridge” (92) as described in International patent ation WO
2013/124474 is arranged in between the second removal cartridge (90) and the bioreactor (50).
Thus, a subpopulation of cells (2a) that is comprised in the tion of cells (2) can be
selected/enriched via this “selection cartridge” (92) as described in . This
subpopulation of cells (2a) can either be transferred into the bioreactor (50), for example, to
undergo serial expansion as described here. Alternatively (not shown), this subpopulation of
cells (2a) can be used for cell based therapy. It is again noted here that the use of a soluble
multimerization reagent as described here allows the design of automated cell purification and
expansion devices which are functionally closed and thus not prone to contamination. In
addition, since soluble multimerization reagent avoids the need for solid phase materials such
as magnetic beads, such cell purification devices can be designed as continuous flow devices.
Fig. 13 shows the expansion kinetics of proliferation of purified CD4+ and CD8+
T responder cells (Tresp) that were stimulated in vitro either with (xCD3/0tCD28 Fab fragments
or with ocCD3/uCD28/0tCD8 that were ibly immobilized on two kinds of a soluble
oligomeric Strep—tactin® mutein acting as e multimerization reagent. The first kind of
oligomeric Strep-tactin® was the fraction of the oligomeric streptavidin mutein (n2 3)
obtained in Example 5 (also referred herein as “conventional Streptactin® backbone”,
illustrated by the triangle symbol with the tip down in Fig. 13), the second kind of this
oligomeric streptavidin mutein used as soluble multimerization t was an oligomer that
was obtained by reacting the soluble oligomeric streptavidin mutein with biotinylated human
serum albumin (HSA) This HSA based e erization reagent is also ed herein
as “large actin® backbone). In the experiments of Fig. 13 the expansion was carried out
without medium exchange. The results for the CD4+ T responder cells are shown in Fig.13A,
the results for the CD8+ T responder cells are shown in Fig. 13B. In this context, it is noted
that the experimentally used soluble erization reagents that were fiinctionalized by
ibly binding first agents, and optionally second and third agents are referred to in the
Figures as “Streptamer® multimers”
Fig. 14 shows the expansion kinetics of proliferation of purified CD4+ and CD8+
T responder cells (Tresp) that were stimulated in vitro with (xCD3/(xCD28 Fab fragments that
were reversibly immobilized nts that were reversibly immobilized with two kinds of
soluble eric Strep—tactin® acting as soluble multimerization reagent. The first kind of
oligomeric Strep-tactin® was the fraction of the oligomeric streptavidin mutein (n2 3)
obtained in Example 5 (also referred herein as “conventional Streptactin® backbone”,
illustrated by the le symbol with the tip on top in Fig. 14), the second kind of this
oligomeric streptavidin mutein used as soluble multimerization reagent was the HSA based
soluble multimerization agent, the above-mentioned “large actin® backbone“). In the
experiments of Fig. 14 the expansion was carried out with medium exchange. The results for
the CD4+ T responder cells are shown in Fig.14, the results for the CD8+ T der cells are
shown in Fig. 143.
Fig. 15 shows the combined data from the results obtained in Figs 13 and 14 for
the expansion kinetics of proliferation of purified CD4+ and CD8+ T responder cells, with
Fig. 15A ing the results for CD4+ T cells and Fig. ISB depicting the results for the
CD8+ T cells. Straight lines are used for the ing with medium exchange on day 3, while
dashed lines depict the values obtained for the degree of expansion without media exchange on
day 3. The data shown in Fig. 15 are normalized on the input cell number. Only data for the
Tresp stimulated with the oligomeric streptavidin mutein (n2 3), the Tresp ated with the
commercially available Dynabeads ive l) and the unstimulated T cells ive
l) are shown but no data on the multimerization reagent with the “large Streptactin®
backbone“.
Fig. 16 shows early cluster formation ofT cells after activation ofpurified CD4+
and CD8+ T responder cells stimulated in vitro with uCD3/0LCD28 Fab fragments that were
reversibly immobilized on the soluble oligomeric streptavidin mutein (n2 3) described in
Example 5. Fig. 16A s the results for CD4+ T cells and Fig. 16B depicts the results for
the CD8+ T cells. Data for the Tresp stimulated with the soluble multimerization reagent (the
oligomeric streptavidin mutein), the Tresp stimulated with the commercially available
Dynabeads (positive control) and the unstimulated T cells (negative control) are shown.
[0048] Fig. 17 shows the expansion kinetics and phenotype of CD3+ central memory T
cells (Tcm) (CD3+CD62L+CD45RA—Tcm) polyclonally stimulated in vitro with
uCD3/0LCD28 Fab fragments that were reversibly immobilized on the soluble oligomeric
streptavidin mutein (with n2 3) described in Example 5. The graphs shown in Fig. 17
represent the degree of proliferation according to the number of cells harvested per time point,
with Fig. 17A showing the proliferation in only IL-2 supplemented media and in Fig. 17B
showing the proliferation in IL-2 and IL-15 supplemented media. Fig. 17C shows a flow-
cytometric analysis of CD62L and CD127 surface expression after 14 days of culture in these
le cytokine milieus.
Fig. 18 shows the kinetics of selective antigen-specific (Ag-specific) expansion
out of a bulk population of purified CD3+CD62L+CD45RA— Tcm responder cells that were
stimulated in vitro with both a peptidezMHC molecule complex (that acts as first agent that
es a primary activation signal to the cells) and (xCD28 Fab fragment (that acts as second
agent that binds the accessory molecule on the surface of the cells) and unstimulated T cells
(negative control) are shown. Both, the complex of antigen-specific peptide with the MHC
molecule and the dCD28 Fab fragment were ibly immobilized on the same e
oligomeric streptavidin mutein (with n2 3) described in Example 5. The peptide used for the
antigen—specific expansion in Fig. 18A was the peptide CRVLCCYVL (SEQ ID NO: 06),
amino acids 309—317 of the immediate-early 1 protein restricted by the HLA-C702 MHC
molecule (described in Ameres et a1, PLOS Pathogens, May 2013, vol. 9, issue 5, 83)
representing an HLA-C7/IE-1 e that is specific for cytomegalovirus (CMV). The MHC I
molecule that presents the peptide carries at its C-terminus of the heavy chain the streptavidin
g e (SAWSHPQFEK(GGGS)2GGSAWSHPQFEK (SEQ ID NO: 07), that is
cially available as Strep-tag®” fiom IBA GmbH, Gottingen, Germany). Fig.
18A shows exemplary flow-cytometric analysis for the on of the Ag-specific cells that
were proliferated using the peptide:MHC-I complex specific for this HLA—C7/IE—1 epitope as
first agent that provides a primary activation signal to the cells reversibly immobilized on the
soluble oligomeric streptavidin mutein. The graphs in Fig.18B to Fig.18E rates the
expansion kinetics of fithher Ag-specificities according to the number of specific
peptidezMHCI multimer—positive cells harvested per time point in analogy to Fig. 18A using
distinct complexes of an antigen-specific e with the MHC I molecule as first agent that
provides a primary activation signal to the cells reversibly immobilized on the soluble
oligomeric streptavidin mutein. In more detail, Fig. 183 shows the expansion of Ag-specific
cells that were expanded using the peptide:MHC-I x specific for the pp65 epitope of
CMV (amino acids 341—350 (QYDPVAALF, (SEQ ID NO: 08)) restricted by HLA—A2402),
Fig. 18C shows the expansion of Ag-specific cells that were expanded using r
peptidezMHC-I complex specific for the pp65 epitope of CMV (amino acids 265-274
RPHERNGFTV, (SEQ ID NO: 09)) restricted by HLA-B702), Fig. 18D shows the expansion
of Ag-specific cells that were proliferated using the peptidezMHC-I complex c for the
hexon 5 epitope of adenovirus (amino acids 114-124 (CPYSGTAYNSL, (SEQ ID NO: 10))
restricted by HLA-B702), Fig. 18E shows the expansion of Ag-specific cells that were
proliferated using the peptide:MHC-I complex specific for the HLA—B7/IE-1309_317 epitope of
CMV (exemplary FACS data see above Fig. 18A). All peptide:MHC molecules bearing the
Twin Strep®-Tag are commercially available from IbaGmbH. In this context, the amino acid
sequences of the HLA—A*2402, HLA-B*0702 and HLA-C*0702 molecules that carry the
“Twin-Strep-tag®” as their C—terminus are shown as SEQ ID NO: 21, 22 and 23 in the
anying Sequence Listings, while the amino acid ce of the [32 microglobulin
(which forms er with the or chain, that means the HLA encoded molecules the respective
MHC I le) is shown as SEQ ID NO: 24 in the accompanying Sequence Listing. In
addition, Fig.18F show exemplary flow-cytometric analysis of CD62L and CD127 surface
sion after 14 days of culture for HLA-B7/Hexon5114_124 ated/expanded cells from
Fig. 18D.
[0050] Fig. 19 shows the kinetics of selective Ag-specific expansion out of purified
CD3+CD62L+CD45RA—Tcm responder cells that were stimulated in vitro with a) antigen
c peptide MHC I complexes and b) uCD28 Fab fragments that were reversibly
immobilized as first and second agent on soluble oligomeric streptavidin muteins. For this
purpose 500.000 CD3+CD62L+CD45RA- responder Tcm cells (Tresp) were stimulated Ag-
specifically using 3 ul of a preparation of Streptactin multimerization reagent fiinctionalized
with 0.5ug peptide:MHC class I complexes equipped with a streptavidin binding peptide (the
specific peptide represents amino acids 114-124 (CPYSGTAYNSL, SEQ ID NO: 10) of the
Hexon 5 protein of the irus restricted by HLA-B0702, see above) and 0.5 ug uCD28
Fab. As an alternative, 4.5 ul of a preparation of Streptactin multimerization reagent loaded
with 0.5ug this peptide2MHC class I complex, 0.5 ug (xCD8 Fab and 0.5ug uCD28 Fab. For
comparison, polyclonal stimulation was med, using 3 ul of a preparation of Streptactin
multimerization reagent (lmg/ml) either loaded with a combination of 0.5ug uCD3 Fab and
0.5 ug (xCD28 Fab. Again as the alternative stimulation condition bed above, 4.5 ul of a
preparation of Streptactin multimers loaded with 0.5 ug 0LCD3 Fab, 0.5ug uCD8 Fab and 0.5ug
(xCD28 Fab was used. Untreated (unstimulated) Tresp cells served as ve control and
Tresp cells ated polyclonal with Dynabeads as positive control. Tresp cells were seeded
in 48-well plates in lml cell culture medium mented with 30U/ml IL-2 and 5ng/ml IL-
. Cells were incubated at 37°C with media exchange every 3 days and cell count was
analyzed after 7 and 14 days. The photographs shown in Fig. 19 represent the degree of cluster
formation on day 5 for Ag-specific stimulation as exemplified for the HLA—B7/Hexon 5
epitope of adenovirus.
Fig. 20 shows the yield and phenotype of expansion of purified CD8+ T
responder cells stimulated in vitro with uCD3/0LCD28 Fab fragments that were reversibly
immobilized on two kinds of soluble oligomeric Strep-tactin® acting a soluble multimerization
reagent. The first kind of oligomeric Strep-tactin® was the fraction of the oligomeric
streptavidin mutein (nmericobtained in Example 5 (conventional backbone), the second kind
ofthis oligomeric streptavidin mutein used as soluble multimerization reagent was the soluble
oligomer described above and referred herein as “large” Streptactin® backbone. In these
experiments, the fraction of the oligomeric conventional streptavidin mutein (n2 3) was also
used as a multimerization reagent that were either fiinctionalized with single Fab fragments
(third bar in Fig. 20A and Fig. 20B) or with a combination of uCD3 and uCD28 Fab-
fragments. Furthermore to the combined stimulation with uCD3/uCD28 Fab fragments, also
an additional uCD8 Fab fragment (commercially available from IBA GmbH, Gottingen,
Germany) was immobilized in order to test whether it is possible to entially stimulate a
specific T cell subpopulation. Fig. 20A shows a graph of bars that ent the degree of
proliferation according to the number of cells harvested at day 6 compared to the negative
controls (unstimulated purified CD8+ T responder cells) and normalized to the positive control
(purified CD8+ T responder stimulated with commercially available ads (beads on
which uCD3 and uCD28 monoclonal antibodies are rsible immobilized). Fig. 203 shows
flow-cytometric analysis of the surface expression of CD8 and the T cell surface le
CD45RO (that is tive ofT cell proliferation and activation) after cell culture. The various
stimulating ions were compared using one-way ANOVA and no significant difference
(us) was detected.
Fig. 21 shows the yield and phenotype for the expansion of purified CD8+ T
der cells ated in vitro with uCD3/0iCD28 Fab fragments that were reversibly
immobilized on soluble oligomeric Strep-tactin® acting as a soluble multimerization reagent
that were either fiinctionalized with single Fab fragments or with a combination of Fab—
fragments (as already described . In these experiments, the CD8+ T responder cells
were stimulated with the soluble multimerization t (the e oligomeric Strep-tactin®
(lmg/ml) of Example 5) which was functionalized with varying amounts of uCD3 and 0iCD28
Fab fragments, optionally together with the (iCD8 Fab fragment described above. The term
,,lx“ ponds to 1.5ug multimerized Streptactin fiinctionalized with 0.5ug uCD3 Fab
fragment alone and 1.5ug multimerized Streptactin fiinctionalized with 0.5ug uCD28 Fab
alone), or 3 ul of a preparation of oligomeric Streptactin loaded with 0.5 ug uCD3 Fab nt
and 0.5ug uCD28 Fab, or 4.5ul of a preparation of Streptactin multimers loaded with 0.5ug
strep-tagged uCD3, 0.5ug strep-tagged 0LCD8 and 0.5ug strep-tagged uCD28 Fab.
Accordingly, the term ,,2x“ corresponds to 3.0 ug multimerized Streptactin fiinctionalized with
lug dCD3 Fab fragment alone and 3.0 ug multimerized Streptactin fianctionalized with lug
dCD28 Fab alone, meaning that twice the amount of immobilized dCD3 Fab fragment was
used. Untreated Tresp cells served as negative control and purified CD8+ T responder
stimulated with commercially available Dynabeads (beads on which (xCD3 and (xCD28
onal antibodies are irreversible immobilized) as positive control. Fig. 21A shows a
graphs in which the bars represent the degree of proliferation according to the number of cells
harvested at day 5 compared to the negative controls and normalized to the positive control.
Fig. 21B shows FACS analysis of CD8 and CD45RO surface expression after cell culture.
Fig. 22 shows the activation of intracellular signaling cascades of transduced
Jurkat cells that have been d to express an dCD19 chimeric antigen receptor (CAR),
and that were ated using the oligomeric Strep-tactin® of Example 5 as soluble
erization reagent. The specificity of a CAR is typically derived from a scFv region
assembled from the antigen-binding region of a monoclonal antibody (mAb) that cally
binds a target/tumor associated antigen such as CD19 and links it to T cell specific signaling
(described in Hudecek et al, Clin Cancer Res. 2013 June 15; 19(12): 3153—3164. In the
experiments the ellular domain (ECD) of CD 19, which contains the l ligand of the
OLCD19 CAR as well as the polyclonal (ngG F(ab)2 fragment that recognizes the IgG4 spacer
(donkey-anti—human F(ab)2 is commercially available from Jackson Immuno ch) within
the dCD19-CAR were also used in this ment as first agent that provides a primary
activation signal to the jurkat cells. The reversibly immobilization to the soluble oligomeric
streptavidin mutein was provided by the streptavidin peptide
SAWSHPQFEK(GGGS)2GGSAWSHPQFEK (SEQ ID NO: 07) that was fused to the C-
terminus of the ECD of CD19 or by the ylated (Fab)2 fragment of the (ngG (since the
streptavidin mutein “m2” binds biotin with reduced affinity, this binding is reversible and can
for example be displaced by addition of an excess of free biotin). In the control experiment of
Fig.22A 300.000 CD3+ Jurkat responder cells (Jresp) were stimulated with varying amounts
of a e of preparations of oligomeric Streptactin (lmg/ml) that was onalized with
the dCD3 Fab and the dCD28 Fab (,,xl“ corresponds to 3ug erized Streptactin
functionalized with 0.5ug aCD3— and 0.5ug aCD28 Fab — polyclonal Streptamer multimer). In
the experiment of Fig. 22B 3 ul of a preparation of the oligomeric Streptactin was
functionalized with 0.5ug (x1) or lug (x2) of the extracellular domain (ECD) of CD19 or with
3 ul of a preparation of the oligomeric Streptactin loaded with 0.5 ug (xl) or lug (x2) (ngG that
recognizes the IgG4 spacer (which are both ecific Streptamer® multimers). Jresp
stimulated with Dynabeads (beads on which dCD3 and 0tCD28 monoclonal antibodies are
rsible lized) or PMA and ionomycin served as positive controls. Jresp cells were
seeded in 1.5ml Eppendorf tubes in 200ul cell culture medium supplemented with 30U/ml IL-
2. Cells were incubated at 37°C and put on ice and lysed after 0 min to 20min of stimulation.
Fig. 23 shows the expansion of purified CD3+ T responder cells stimulated in
vitro with 0LCD28 Fab fragments that were reversibly immobilized on the soluble
oligomeric Strep-tactin® of Example 5 that served a soluble multimerization reagent. In one
experiment, in addition to xCD28 Fab fragments, also an (xCD8 Fab fragment
commercially available from IBA GmbH, Gottingen, Germany ogue number 6
203) was immobilized on the soluble oligomer of the streptavidin mutein in order to test
whether it is possible to preferentially stimulate in vitra the CD8+ T cell subpopulation within
the bulk CD3+ culture with a multimerization reagent of the invention having reversibly
immobilized thereon also an uCD8 Fab fragment. In more detail, 500.000 purified CD3+
responder T cells (Tresp) were stimulated with 3 ul of a preparation of oligomeric Streptavidin
(lmg/ml) loaded with a combination of 0.5 ug of the (xCD3 and 0.5 ug of the 0LCD28 Fab. As an
alternative approach, 4.5 ul of the Streptactin oligomer were loaded with 0.5 ug aCD3, 0.5 ug
uCD8 Fab and 0.5ug 0LCD28 Fab described above. Unstimulated Tresp cells served as
negative control and Tresp stimulated with Dynabeads (beads on which uCD3 and uCD28
monoclonal antibodies are irreversible immobilized) served as positive control.
Fig. 24 depicts exemplary strategies for the generation of oligomeric streptavidin
muteins that can be used as soluble multimerization reagent of the invention. Fig. 24A shows
that in a first step, the streptavidin mutein “m2” (SAm2) that comprises the amino acid
sequence lle44-Gly45-Ala46-Arg47 (SEQ ID NO: 03) at sequence positions 44 to 47 ofwild type
streptavidin is used for generation of oligomeric avidin muteins having a “conventional
ne”. In a second step, oligomeric soluble streptavidin muteins having a “large
backbone” can be generated by either by coupling of streptavidin mutein with biotinylated
carrier protein such as human serum n (HSA) or by ng the streptavidin muteins
with synthetic carriers such as PEG. Fig. 24B: Biotinylation of human serum albumin (HSA).
DETAILED DESCRIPTION OF THE INVENTION
The present ion provides s, kits and an tus for expanding a
population of cells or for inducing a population ofT cells to proliferate.
The term “population of cells” as used herein asses all cells which can be
expanded by binding to a cell surface receptor a first agent that es a primary activation
signal to the cells. It is also possible that for expansion of the population of cells, binding of
second agent to a second cell surface receptor (accessory molecule) might be needed to
produce a co-stimulatory signal ed for expansion of the cells. In some embodiments the
cell population may be a tion of lymphocytes including, but not limited a population of
B cells, a population of T cells or a population of natural killer cells. Illustrative examples of
cell populations are B cells carrying CD40 or CD137 (both cell population can be proliferated
upon binding of only a first agent that provides an activation signal, for example 4-1BB ligand;
or an aCD40 antibody molecule or an uCD137 antibody le (see for example Zhang et
a1., 2010, J Immunol, 184:787-795)). Other illustrative examples for agents (either first or
second) that may be used for the expansion ofB cells are agents that bind to IgG, CD19, CD28
or CD14, for example uCD19, ngG, uCD28, or uCD14 antibody molecules. It is also
envisioned that first or second agents for the expansion ofB cell may comprise ligands for toll
like receptors or interleukins, such as IL-21 (see for e Dienz O, et a1. 2009. J. Exp.
Med. ). It is noted that lipopolysaccharide dependent activation of B cells is also
encompassed in the present invention, as a lipopolysaccharide can also be used as first agent
and can be ed with a binding partner C1 as used herein. Other illustrative examples of
suitable cell populations include T cell population that expand after being activated by binding
of a first agent to TCR/CD3 and binding of a second agent to an accessory molecule on the T
cell such as CD28. In this case, the first agent stimulates a TCPUCDS complex-associated
signal in the T cells and the second agent provides a secondary stimulus by binding CD28 as
ory molecule. Agents that can be used for the expansion of T cells may also include
eukins, such as IL—2, IL-7, IL-15, or IL—21 (see for example Cornish et a1. 2006, Blood.
108(2):600-8, Bazdar and Sieg, 2007, Journal of Virology, 2007, 81(22): 12670-12674, Battalia
et a1, 2013, Immunology, 139(1):109-120). Other illustrative examples for agents that may be
used for the expansion of T cells are agents that bind to CD8, CD45 or CD90, such as uCD8,
0LCD45 or (1CD90 antibodies. rative examples of T cell population including antigen-
specific T cells, T helper cells, cytotoxic T cells, memory T cell (an illustrative example of
memory T-cells are CD62L+CD8+ specific central memory T cells) or regulatory T cells (an
illustrative example of Treg are CD4+CD25+CD45RA+ Treg cells). The term “T cell
(population)” as used herein also includes T cells that comprise a chimeric antigen or
(CAR) that is also known as artificial T cell receptors or chimeric T cell receptors. Thus, a T
cell tion that comprises a chimeric antigen receptor can also be ed using the
methods, reagents and devices of the present invention. See in this respect also Example 15 in
which Jurkat cells that express a chimeric CD19 specific antigen receptor (CAR) were
stimulated using a soluble multimerization reagent of the present invention. Another
illustrative example of a suitable cell population includes natural killer cells (NK cells), which
may for example be expanded with agents that bind to CD16 or CD56, such as for example
(xCDl6 or 0LCD56 antibodies. In illustrative example for such an (xCDl6 antibody is the
antibody 3G8 with a VH sequence set forth in SEQ ID NO: 25 and a VL ce set forth in
SEQ ID NO: 26 (see for example Hoshino et al, Blood. 1991 Dec 15,78(l2):3232—40.).
Another agent that may be used for expansion of NK cells may be IL-15 (see for example
Vitale et al. 2002. The Anatomical Record. 266287-92). Yet another illustrative example of a
suitable cell population includes monocytes, which may for instance be expanded using an
agent that binds to CD14, such as an uCDl4 antibody molecule. The cell tion can be of
any mammalian origin, including but not d to human, rabbit, guinea pig, squirrel,
hamster, cat, dog, lemur, goat, pig, horse, rhesus monkey, macaque, or a chimpanzee.
Thus, in line with the above, this invention pertains to methods for selectively
inducing ex vivo ion of a population of cells such as B cells, T cells or natural killer
cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells. In
addition, the proliferation of these cells such as B cells or T cells can be induced without the
need for antigen, thus providing an expanded cell population such as a T cell population which
is polyclonal with respect to antigen reactivity. The methods disclosed herein may e for
ned proliferation of a selected population of T cells such as CD4+ or CD8+ T cells over
an extended period of time to yield a multi—fold increase in the number of these cells ve to
the original T cell population. In l, in case of a l) expansion of a lymphocyte
population as described herein, all progeny may share the same antigen city as the cell
population that was selected for expansion.
Also in line with the above, provided by this invention are methods for expanding
a population of antigen c T cells. To produce a population of antigen specific T cells, T
cells are contacted with an antigen in a form suitable to r a primary tion signal in
the T cell, i.e., the antigen is presented to the T cell such that a signal is triggered in the T cell
through the TCR/CD3 complex. For example, the antigen can be presented to the T cell by an
antigen presenting cell in conjunction with an MHC molecule. An antigen presenting cell, such
as a B cell, macrophage, monocyte, tic cell, Langerhans cell, or other cell which can
present antigen to a T cell, can be incubated with the T cell in the presence of the antigen (e.g.,
a e antigen) such that the antigen presenting cell presents the antigen to the T cell.
Alternatively, a cell expressing an antigen of interest can be incubated with the T cell. For
example, a tumor cell expressing associated antigens can be incubated with a T cell
together to induce a tumor-specific response. Similarly, a cell infected with a pathogen, e. g., a
Virus, which presents antigens of the pathogen can be incubated with a T cell. Following
antigen specific activation of a population of T cells, the cells can be expanded in accordance
with the methods of the invention. For example, after antigen specificity has been established,
T cells can be expanded by culture with an anti-CD3 antibody (used as first agent) and an anti-
CD28 antibody (used as second agent) according to the s described herein. In another
embodiment, the first agent can be an MHC I: peptide complex, which binds to an antigen
specific T cell population. In such an embodiment, any antigen specific e that is known
and that can be complexed with the tive MHC I molecule can be used. See in this
respect Examples 11 and 12 in which selective Antigen-specific expansion ofTom responder
cells out of bulk CD3+ central memory T cells was exemplied for four different antigen-
specific cells. Alternatively, it is also le to use as first agent the natural ligand of a
receptor that triggers of cell expansion. See in this respect Example 15 in which the
extracellular domain of CD19 caused the activation of intracellular signaling cascades of
transduced Jurkat cells that were modified to express chimeric CD19 binding antigen receptor
(CAR).
The sample of the cell population can be from any suitable source, typically all
sample of a body tissue or a body fluid such as blood. In the latter case, the sample might for
e, be a population of peripheral blood mononucleated cells (PBMC) that can be
obtained by standard isolation methods such a ficoll gradient of blood cells. The cell
population to be ed can however also be in purified form and might have been isolated
using an reversible cell staining/isolation logy as described patent in US patent
7,776,562, US patent 8,298,782, International Patent application WOO2/054065 or
International Patent Application WO2013/011011. Alternatively, the tion of cells can
also be obtained by cell sorting via negative magnetic immunoadherence as described in US
Patent 6,352,694 B1 or European Patent EP 0 700 430 B1. If an isolation method described
here is used in basic research, the sample might be cells of in vitro cell culture experiments.
The sample will typically have been prepared in form of a fluid, such as a solution or
dispersion.
In line with the above, in one embodiment the ion es an in vitro-
method of expanding a population of cells, comprising ting a sample comprising a
population of cells with a multimerization reagent. The multimerization reagent has reversibly
immobilized thereon (bound thereto) a first agent that provides a primary activation signal to
the cells, wherein the multimerisation reagent comprising at least one binding site Zl for the
reversible binding of the first agent. The first agent comprises at least one binding partner Cl,
wherein the binding r Cl is able of reversibly binding to the binding site Zl of the
multimerization reagent, wherein the first agent is bound to the multimerization reagent via the
reversible bond formed between the binding partner C1 and the binding site Z1. The first agent
binds to a receptor le on the e of the cells, thereby providing a y activation
signal to the cells and thereby activating the cells.
In another embodiment, the invention provides a method, wherein the
erization agent has reversibly immobilized thereon (bound thereto) a second agent that
stimulates an accessory molecule on the e of the cells. The second agent comprises a
binding r C2, wherein the binding partner C2 is able of being reversibly bound to a
binding site Z2 of the multimerization reagent, wherein the second agent is bound to the
multimerization reagent via the reversible bond formed between the binding partner C2 and
the binding site Z2. The second agent binds to the accessory le on the surface on the
surface of the cells, thereby stimulating the activated cells. In this embodiment the first agent
may stimulate a TCIVCD3 complex—associated signal in the T cells and may be a g
agent that specifically binds CD3. In this embodiment the accessory molecule on the T cell
may be CD28 and the second agent that binds the accessory molecule is a binding reagent that
specifically binds CD28. In this case, the first agent that specifically binds CD3 may be
selected from the group consisting of an anti-CD3-antibody, a divalent antibody fragment of
an anti-CD3 dy, a monovalent antibody fragment of an anti-CD3-antibody, and a
proteinaceous CD3 binding le with antibody-like binding ties. Also the second
agent that specifically binds CD28 may be selected from the group consisting of an anti—CD28-
antibody, a divalent antibody nt of an anti-CD28 antibody, a monovalent antibody
nt of an anti-CD28-antibody, and a proteinaceous CD28 binding molecule with
antibody-like binding ties. The divalent antibody fragment may be an (Fab)2’-fragment,
or a divalent single-chain Fv fragment while the monovalent antibody fragment may be
selected from the group consisting of a Fab fragment, a Fv fragment, and a -chain Fv
nt (scFv). A proteinaceous CD3 or CD28 binding molecule with antibody-like binding
properties may be an aptamer, a mutein based on a polypeptide of the lipocalin family, a
glubody, a protein based on the ankyrin scaffold, a protein based on the crystalline scaffold, an
adnectin, and an avimer.
In general the first and the second agent that is used in the present ion may,
for instance be, an antibody, a fragment thereof and a proteinaceous binding molecule with
dy—like fianctions. Examples of (recombinant) antibody fragments are Fab fragments, Fv
fragments, single-chain Fv fragments (scFv), a divalent antibody fragment such as an (Fab)2'-
fragment, diabodies, triabodies es, P., et al., FEBS Lett (1997) 409, 437-441), decabodies
(Stone, E., et al., Journal of Immunological Methods (2007) 318, 88—94) and other domain
antibodies (Holt, L.J., et al., Trends Biotechnol. (2003), 21, 11, 484-490). In some
embodiments one or more binding sites of the first or second agent may be a bivalent
proteinaceous ial binding molecule such as a dimeric lipocalin mutein that is also known
as "duocalin". In some embodiments the receptor binding reagent may have a single second
binding site, i.e., it may be monovalent. Examples of monovalent first or second agents
include, but are not limited to, a monovalent antibody fragment, a proteinaceous binding
molecule with dy—like g ties or an MHC le. Examples of monovalent
antibody fragments include, but are not limited to a Fab fragment, a Fv fragment, and a single-
chain Fv fragment , including a divalent single—chain Fv fragment.
As ned above, an example of a proteinaceous binding molecule with
antibody—like fianctions is a mutein based on a polypeptide of the lipocalin family (see for
example, WO 03/029462, Beste et al., Proc. Natl. Acad. Sci. USA. (1999) 96, 1898-1903).
Lipocalins, such as the bilin binding n, the human neutrophil gelatinase-associated
lipocalin, human Apolipoprotein D or human tear lipocalin possess natural —binding sites
that can be modified so that they bind a given target. Further examples of a proteinaceous
binding molecule with antibody-like binding properties that can be used as a receptor binding
reagent that specifically binds to the receptor molecule include, but are not d to, the so-
called glubodies (see e.g. international patent application WO 79), proteins based on the
ankyrin scaffold (Mosavi, L.K., et al., Protein Science (2004) 13, 6, 1435-1448) or crystalline
scaffold (e.g. international patent application WO 01/04144) the proteins described in Skerra,
J. Mol. Recognit. (2000) 13, 167-187, AdNectins, tetranectins and avimers. Avimers, including
multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains,
n so called A-domains that occur as strings of multiple domains in l cell surface
receptors (Silverman, J., et al., Nature Biotechnology (2005) 23, 1556-1561). Adnectins,
derived from a domain of human fibronectin, contain three loops that can be engineered for
immunoglobulin—like binding to targets (Gill, D.S. & Damle, N.K., Current Opinion in
Biotechnology (2006) 17, 653-658). Tetranectins, derived from the respective human
imeric n, likewise contain loop regions in a C-type lectin domain that can be
ered for desired binding (ibid.). Peptoids, which can act as protein ligands, are oligo(N-
alkyl) glycines that differ from peptides in that the side chain is connected to the amide
nitrogen rather than the or carbon atom. ds are typically resistant to proteases and other
ing enzymes and can have a much higher cell permeability than peptides (see e.g.
Kwon, Y.-U., and Kodadek, T., J. Am. Chem. Soc. (2007) 129, 1508—1509). Yet further
examples of suitable proteinaceous binding molecules are an ke domain, a Kringle-
domain, a fibronectin type I domain, a fibronectin type II , a fibronectin type III
domain, a PAN domain, a Gla domain, a SRCR , a Kunitz/Bovine pancreatic trypsin
tor domain, tendamistat, a Kazal—type serine se inhibitor domain, a Trefoil (P-type)
domain, a von Willebrand factor type C domain, an latoxin-like domain, a CUB
domain, a thyroglobulin type I repeat, LDL-receptor class A domain, a Sushi domain, a Link
domain, a Thrombospondin type I domain, an immunoglobulin domain or a an
immunoglobulin—like domain (for e, domain antibodies or camel heavy chain
antibodies), a C—type lectin domain, a MAM domain, a von rand factor type A ,
a Somatomedin B domain, a WAP-type four disulfide core domain, a F5/8 type C domain, a
Hemopexin domain, an SH2 domain, an SH3 domain, a Laminin-type EGF-like domain, a C2
domain, "Kappabodies" (cf. 111. et al., Protein Eng (1997) 10, 949—57, a so called ody"
(Martin et al., EMBO J (1994) 13, 5303-5309), a diabody (cf. Holliger et al., PNAS USA
(1993)90, 6444-6448), a so called "Janusis" (cf. Traunecker et al., EMBO J (1991) 10, 3655-
3659, or Traunecker et al., Int J Cancer (1992) Suppl 7, 51-52), a nanobody, a microbody, an
affilin, an affibody, a knottin, ubiquitin, a zinc-finger protein, an autofluorescent protein or a
leucine-rich repeat protein. An example of a nucleic acid molecule with antibody-like
functions is an aptamer. An aptamer folds into a defined three-dimensional motif and shows
high affinity for a given target structure.
[0065] Turning now the multimerization reagent, the binding sites Z1 and Z2 of the
multimerization agent can be identical (see also the Example of Fig. 3). In this case, a single
multimerization agent may be used.
In the embodiment that a reversibly bond first and, optionally second agent is
used, the multimerization reagent may be immobilized on a solid surface. Any solid surface
(support) can be used for the immobilization of the multimerization reagent. Illustrative
examples of solid surfaces on which the erization t can be immobilized include a
magnetic bead, a polymeric bead, a cell culture plate, a microtiter plate, a membrane, or a
hollow fiber. Hollow fibers are, for example, used as bioreactor in the Quantum® Cell
Expansion System, available from TerumoBCT Inc. ood, CO, USA). The
erization reagent is usually covalently ed to the solid support, however, non-
covalent interactions can also be used for immobilization, for example on plastic substrates, if
wanted. As also explained in more detail below, the multimerization reagent can, for example,
be a streptavidin or avidin mutein that reversibly binds a streptavidin binding e. Such
streptavidin muteins can be covalently attached to any surface, for example, resin (beads) used
for chromatography ation and are commercially available in such form from IBA
GmbH, Gottingen, for example, as Strep-Tactin® Sepharose, Strep-Tactin® Superflow®,
Strep-Tactin® Superflow® high capacity or Strep-Tactin® MacroPrep®. Other illustrative
es multimerization ts that are readily commercially available are immobilized
metal affinity chromatography (IMAC) resins such as the TALON® resins urg,
Leusden, The Netherlands) that can be used for the reversible immobilization of oligo-
histidine tagged (his-tagged) proteins in general, meaning here, for the reversible binding of a
first or a second agent that carries as first binding partner C1 or second binding partner C2 an
oligohistidine tag such as an penta- or hexa-histidine tag. Other examples of multimerzation
reagents are calmodulin sepharose available from GE Life es which can be used
together with a first or second agent that comprises a calmodulin binding peptide as binding
partner C1 or C2 or sepharose, to which glutathion is coupled. In the case, the binding partner
C1 or C2 is glutathion-S-transferase.
[0067] In other embodiments of the method of the invention the multimerization reagent
can be in a soluble form. In principle, the same multimerization agents can be used as in the
case of a multimerization reagent that is immobilized on a solid support. The multimerization
reagent is soluble form, can for e, be a streptavidin mutein oligomer, a calmodulin
oligomer, a compound (oligomer) that provides least two chelating groups K, wherein the at
least two chelating groups are capable of binding to a tion metal ion, y rendering
moiety A capable of binding to an oligohistidine affinity tag, multimeric glutathione-S-
transferase, or a biotinylated carrier protein.
As explained above, the first and second agent has, in addition to the binding site
that is able to bind the respective cell surface receptor molecule, a binding partner C1 or C2
(which will be referred to as “binding partner C” in the following for the ease of reference).
This binding partner C is able to bind to a binding site Z of the multimerization reagent (Z
means either binding site Zl or g site Z2 of the multimerization reagent) C. The non-
covalent bond that is formed between the g r C that is included in the first or
second agent and the binding Site(s) Z of the multimerization reagent may be of any d
strength and affinity, as long as it is disruptable or reversible under the conditions under which
the method of the invention is performed. The dissociation nt (KD) of the binding
between the binding partner C that is included in the receptor binding reagent and the binding
site Z of the multimerization reagent may have a value in the range from about 10‘2 M to about
‘13 M. Thus, this reversible bond can, for example, have a KD from about 10'2 M to about 10'
M, or from about 10‘3 M to about 10'12 M or from about 10'4 M to about lO‘llM, or from
about 10‘5 M to about IO'IOM. The KD of this bond as well as the KB, koff and kon rate of the
bond formed between the binding site B of the receptor binding reagent and the receptor
le can be determined by any suitable means, for example, by fluorescence titration,
equilibrium is or surface plasmon nce. The receptor molecule g reagent may
include at least one, including two, three or more, second binding partners C and the affinity
reagent may include at least two, such as three, four, five, six, seven, eight or more binding
sites for the binding partner that is included in the or molecule binding reagent. As
described in US patent 7,776,562, US patent 8,298,782 or International Patent application WO
2002/054065 any combination of a binding partner C and an affinity agent with one or more
corresponding binding sites Z can be chosen, as long as the binding partner C and the binding
site Z of the affinity agent are able to reversibly bind or erize in a (multivalent)
complex, which typically goes along with an avidity effect.
[0069] The binding partner included in the first or second agent may be an oligopeptide,
a polypeptide, a protein, a c acid, a lipid, a saccharide, an oligosaccharide, or a
polysaccharide. Such a binding partner has a higher affinity to the binding site of the
erization reagent than to other matter. Examples of a respective binding partner include,
but are not limited to, an immunoglobulin molecule, a nt thereof and a proteinaceous
binding le with antibody-like functions.
In some embodiments the binding partner C that is ed in the first or second
agent includes biotin and the affinity reagent includes a avidin analogue or an avidin
analogue that reversibly binds to .
In some embodiments the binding partner C that is included in the first or second
agent includes a biotin analogue that reversibly binds to streptavidin or avidin, and the affinity
reagent includes streptavidin, avidin, a streptavidin analogue or an avidin analogue that
reversibly binds to the respective biotin analogue.
In some r embodiments the binding partner C that is included in the first or
second agent includes a streptavidin or avidin binding peptide and the affinity reagent includes
avidin, avidin, a streptavidin analogue or an avidin analogue that reversibly binds to the
respective streptavidin or avidin binding peptide.
In some embodiments the g partner that is included in the first or second
agent may include a streptavidin-binding peptide Trp-Ser-His-Pro-Gln—Phe-Glu-Lys (SEQ ID
NO: 01) and the affinity reagent may e a streptavidin mutein (analogue) that comprise
the amino acid sequence Thr45-Ala46—Arg47 (SEQ ID NO: 02) at sequence ons 44
to 47 of wild type streptavidin or the streptavidin mutein (analogue) that comprises the amino
acid sequence 11e44-G1y45-A1a46-Arg47 (SEQ ID NO: 03) at sequence positons 44 to 47 ofwild
type streptavidin, both of which are described in US patent 6,103,493, for example, and are
commercially ble under the trademark Strep-Tactin®. The streptavidin binding peptides
might, for example, be single peptides such as the “Strep-tag®” described in US patent
,506,121, for example, or streptavidin binding peptides having a sequential arrangement of
two or more individual binding modules as described in International Patent Publication WO
018 or US patent 7,981,632.
In some embodiment the binding partner C of the first or second agent includes a
moiety known to the skilled artisan as an affinity tag. In such an embodiment the affinity
t includes a corresponding binding partner, for example, an dy or an antibody
fragment, known to bind to the affinity tag. As a few illustrative examples of known affinity
tags, the binding partner that is included in the first or second agent may include an
istidine, an globulin domain, maltose-binding protein, glutathione-S-transferase
(GST), chitin binding protein (CBP) or doxin, calmodulin binding peptide (CBP),
FLAG’-peptide, the HA-tag (sequence: Tyr-Pro-Tyr-Asp-Val-Pro-Asp—Tyr-A1a, (SEQ ID
NO: 11)), the VSV-G-tag (sequence: Tyr-Thr—Asp-Ile—Glu—Met-Asn—Arg-Leu-G1y—Lys, (SEQ
ID NO: 12)), the HSV-tag (sequence: Gln-Pro-Glu-Leu-A1a-Pro-G1u-Asp-Pro-G1u-Asp, (SEQ
ID NO: 13)), the T7 epitope (Ala-Ser-Met-Thr-Gly-Gly-Gln-Gln-Met-Gly, (SEQ ID NO: 14)),
maltose binding protein (MBP), the HSV epitope of the sequence Gln-Pro-Glu-Leu-Ala-Pro-
Glu-Asp-Pro-Glu-Asp (SEQ ID NO: 13) of herpes simplex virus rotein D, the “myc”
epitope of the transcription factor c-myc of the sequence Glu-Gln-Lys-Leu-Ile-Ser-Glu—Glu-
Asp-Leu (SEQ ID NO: 15), the V5-tag (sequence: Gly-Lys—Pro-Ile-Pro-Asn-Pro-Leu-Leu—Gly-
Leu-Asp-Ser-Thr, SEQ ID NO: 16), or glutathione-S-transferase (GST). In such an
embodiment the complex formed between the one or more g sites ofthe multimerisation
t, in this case an antibody or antibody fragment, and the antigen can be disrupted
competitively by adding the free antigen, i.e. the free peptide (epitope tag) or the free protein
(such as MBP or CBP). The affinity tag might also be an oligonucleotide tag. Such an
oligonucleotide tag may, for ce, be used to hybridize to an oligonucleotide with a
complementary sequence, linked to or included in the affinity reagent.
In some embodiments the binding n the binding partner C that is included
in the first or second agent and one or more binding sites of the multimerization reagent occurs
in the presence of a divalent, a ent or a tetravalent cation. In this regard in some
embodiments the multimerization reagent es a divalent, a ent or a tetravalent
cation, typically held, e.g. complexed, by means of a suitable chelator. The binding partner that
is included in the receptor g reagent may in such an embodiment include a moiety that
includes, e.g. complexes, a divalent, a trivalent or a tetravalent cation. Examples of a
respective metal chelator, include, but are not d to, ethylenediamine, ethylene-
diaminetetraacetic acid (EDTA), ethylene glycol tetraacetic acid (EGTA), diethylenetri-
aminepentaacetic acid (DTPA), N,N-bis(carboxymethyl)glycine (also called nitrilotriacetic
acid, NTA), or l,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA). As an
example, EDTA forms a complex with most monovalent, divalent, ent and tetravalent
metal ions, such as e.g. calcium (Ca2+), ese (Mn2+), copper (Cu2+), iron (Fe2+), cobalt
(Co3+) and zirconium (Zr4+), while BAPTA is specific for Ca2+. As an rative e, a
standard method used in the art is the formation of a complex between an oligohistidine tag
and copper (Cu2+), nickel (Ni2+), cobalt , or zinc (Zn2+) ions, which are presented by
means of the chelator otriacetic acid (NTA).
In some embodiments the binding partner C that is included in the first or second
agent includes a calmodulin binding peptide and the affinity reagent includes multimeric
calmodulin as described in US Patent 5,985,658 or as described herein with reference to Figure
2, for example. In some embodiments the binding partner C that is included in the first or
second agent includes a FLAG peptide and the affinity reagent includes an antibody that binds
to the FLAG peptide, e.g. the FLAG peptide, which binds to the monoclonal antibody 4E1 l as
described in US Patent 4,851,341. In one embodiment the binding partner C that is included in
the first or second agent includes an oligohistidine tag and the affinity t includes an
antibody or a transition metal ion binding the oligohistidine tag. The disruption of all these
binding complexes may be accomplished by metal ion chelation, e.g. calcium chelation, for
instance by adding EDTA or EGTA ). Calmodulin, antibodies such as 4Ell or chelated
metal ions or free chelators may be multimerized by conventional methods, e.g. by
biotinylation and complexation with streptavidin or avidin or multimers thereof or by the
introduction of carboxyl residues into a polysaccharide, e.g. dextran, essentially as described in
Noguchi, A, et al. Bioconjugate Chemistry (1992) 3, 132-137 in a first step and linking
calmodulin or antibodies or chelated metal ions or free chelators via primary amino groups to
the carboxyl groups in the polysaccharide, e.g. dextran, backbone using conventional
carbodiimide try in a second step. In such embodiments the binding between the
binding partner C that is included in the first or second agent and the one or more binding sites
Z of the multimerization reagent can be disrupted by metal ion chelation. The metal chelation
may, for e, be accomplished by addition of EGTA or EDTA.
In some embodiments, in particular, if the multimerization reagent is in soluble
form and is based on streptavidin or , it is an oligomer or a polymer of streptavidin or
avidin or of any mutein (analogue) of streptavidin or avidin. The binding site Z is the l
biotin binding of avidin or streptavidin. The respective oligomer or polymer may be
crosslinked by a polysaccharide. In one embodiment ers or rs of streptavidin or
of avidin or of muteins (analogs) of streptavidin or of avidin are prepared by the introduction
of yl residues into a polysaccharide, e. g. dextran, essentially as described in Noguchi,
A, et al., Bioconjugate Chemistry (1992) 3,132-137 in a first step. Then streptavidin or avidin
or analogues thereof may be linked via y amino groups of al lysine residue and/or
the free N—terminus to the carboxyl groups in the n backbone using conventional
carbodiimide chemistry in a second step. In addition, cross-linked oligomers or polymers of
streptavidin or avidin or of any mutein gue) of streptavidin or avidin may also be
obtained by crosslinking individual streptavidin or avidin molecules (the tetrameric
homodimer of streptavidin or avidin is referred herein as an “individual molecule” or st
building block of a respective oligomer or polymer) via bifunctional molecules, serving as a
linker, such as glutardialdehyde or by other methods described in the art. It is, for example,
possible to generate oligomers of avidin muteins by introducing, in a first step, thiol
groups into the streptavidin mutein (this can, for example, be done by on the streptavidin
mutein 2—iminothiolan (Trauts reagent) and by activating, in a separate reaction amino groups
available in the streptavidin mutein. This activation of amino groups can be achieved by
reaction of the avidin mutein with a cially available heterobifunctional
crosslinkers such as sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-l-carboxylate
(sulfo SMCC) or Succinimidyl[(B-maleimidopropionamido)hexanoate (SMPH). In a second
step, the two reaction products so obtained are mixed together, leading to the reaction of the
thiol groups contained in the one batch of modified streptavidin mutein with the activated (by
maleimid fiinctions) amino acids of the other batch of modified avidin mutein. By this
reaction, multimers/oligomers of the streptavidin mutein are . These oligomers can
have any suitable number of “individual molecule” or streptavidin ng block” higher than
3 and the oligomerization degree can be varied according to the reaction condition (see Fig.
24). After reacting these two batches of the modified streptavidin mutein, the oligmeric soluble
multimerization t is typically isolated via size ion chromatography and any
desired fraction can be used as multimerization reagent. Typically, the oligomers do not have
(and do not need to have) a single lar weight but they usually observe a statistical
weight distribution such as Gaussian distribution. Any er with more than three
streptavidin homotetramers (building blocks; (n2 3)) can be used as soluble multimerization
reagent. The oligomers might have, for example from 3 to 25 vidin mutein
homotetramers. With a molecular weight of about 50 kDa for streptavidin muteins such as the
mutein “ml” or “m2” described in more detail below, these soluble oligomers have a
molecular weight from about 150 kDa to about 1250 kDa. Since each streptavidin
molecule/mutein has four biotin binding sites such a multimerization reagent provides 12 to
100 binding sites 21 (and Z2) as described herein.
In accordance with the above disclosure, in addition to such oligomeric
multimerization reagents that only contain cross-linked streptavidin tramers, it is
possible to react tetrameric streptavidin muteins to a carrier to obtain multimerization reagents
that are used in the present invention. In addition to the above described reaction with a
ccharide, it is also possible to use physiologically or pharmaceutically acceptable
proteins such as serum albumin (for example human serum albumin (HSA) or bovine serum
n (BSA) as carrier protein. In such a case, the streptavidin mutein (either as individual
homo-tetramer or also in the form of oligomers with n2 3) can be coupled to the carrier n
via non—covalent interaction. For this purpose, biotinylated BSA (which is commercially
available from various ers such as ThermoFisher Scientific, Sigma Aldrich or
Vectorlabs, to name only a few) can be reacted with the streptavidin mutein. When so doing,
some of the streptavidin oligomers will non—covalently bind via one or more biotin g
sites (Z1, Z2) to the biotinylated carrier protein, leaving the majority of the binding sites (Z1,
Z2) of the oligomer ble for binding the agents such as the first agent and optionally the
second agent and any further agent as described herein. Thus, by such an approach a soluble
multimerization reagent with a multitude ofbinding sites Z1 can be iently prepared (see
Fig. 24). Alternatively, a streptavidin mutein (either as individual homo-tetramer or also in the
form of oligomers with n2 3) can be covalently coupled to a synthetic carrier such as a
polyethylene glycol (PEG) molecule. Any suitable PEG molecule can be used for this e,
as long as the PEG molecule and the respective multimerization t is soluble. Typically,
PEG molecule up to a molecular weight of 1000 Da are all soluble in water or culture media
that may be used in the present invention. Such PEG based multimerization reagent can be
easily prepared using commercially available activated PEG les (for e, PEG-
NHS derivatives ble from NOF North a Corporation, Irvine, California, USA, or
activated PEG derivatives available from Creative PEGWorks, Chapel Hills, North Carolina,
USA) with amino groups of the streptavidin mutein.
[0079] Under streptavidin or wild-type streptavidin (wt-streptavidin), the amino acid
ce disclosed by Argarana et al., Nucleic Acids Res. 14 (1986) 1871—1882 is referred to.
Streptavidin muteins are polypeptides which are distinguished from the sequence of wild-type
streptavidin by one or more amino acid substitutions, deletions or additions and which retain
the binding ties of wt—streptavidin. Streptavidin-like polypeptides and streptavidin
muteins are polypeptides which essentially are immunologically equivalent to wild-type
streptavidin and are in particular capable of g biotin, biotin derivative or biotin
analogues with the same or different affinity as wt-streptavidin. Streptavidin-like polypeptides
or streptavidin muteins may contain amino acids which are not part of wild-type streptavidin
or they may include only a part of wild-type streptavidin. Streptavidin-like polypeptides are
also polypeptides which are not identical to ype avidin, since the host does not
have the enzymes which are required in order to transform the host-produced ptide into
the structure of wild-type streptavidin. The term “streptavidin” also includes streptavidin
tetramers and streptavidin dimers, in particular streptavidin tramers, streptavidin
homodimers, streptavidin heterotetramers and strepavidin heterodimers. Each subunit normally
has a binding site for biotin or biotin analogues or for streptavidin-binding peptides. Examples
of streptavidins or streptavidin muteins are mentioned, for example, in WO 86/02077, DE
19641876 Al, US 6,022,951, WO 98/40396 or WO 96/24606.
In a preferred embodiment, streptavidin muteins that are used as multimerization
reagent are those streptavidin s which are described in US Patent 6,103,493 and also in
DE 196 41 8763. These streptavidin muteins have at least one on within the region of
amino acid positions 44 to 53, based on the amino acid sequence of wild-type streptavidin.
ence is given to muteins of a minimal streptavidin, which start N-terminally in the region
of amino acids 10 to 16 of wild-type streptavidin and end C-terminally in the region of amino
acids 133 to 142 of wild-type streptavidin. Examples of such preferred streptavidin muteins
have a hydrophobic aliphatic amino acid instead of Glu at position 44, any amino acid at
position 45, a hydrophobic aliphatic amino acid at position 46 or/and a basic amino acid
instead of Val at position 47. The streptavidin mutein may be a mutein that comprises the
amino acid sequence Val44-Thr45-Ala46-Arg47 (SEQ ID NO: 02) at sequence positions 44 to 47
or the streptavidin mutein (analog) that comprises the amino acid sequence lle44—Gly45-Ala46-
Arg47 (SEQ ID NO: 03) at sequence positions 44 to 47 of wild type streptavidin., Such muteins
are described in US patent 6,103,493, for example, and are commercially available from IBA
GmbH in the form of mutein “ml” and mutein “m2” under the trademark Strep-Tactin®.
[0081] A method according to the present invention may in some embodiments be used
to deplete a sample of ts that have previously been used in cell ion. The first or
second agent and the respective free partner (the competition agent) may, for ce, be
present included in the eluate of an expansion method as described above. Using a method
according to the invention such reagents may be at least essentially, including entirely
removed from a , e.g. from a cell population. As an illustrative example, a first or
second agent as defined above may be depleted from a sample to levels that are below the
detection limit of e.g. FACS or Western Blot. A competition t (free first or second
binding partner or analogue thereof) may have been used in order to terminate and control the
expansion and release the cell population form the multimerization agent. This competition
reagent may have a binding site that is capable of specifically binding to the binding site Z of
the affinity reagent in a al cartridge” of WC 2013/124474. In such an embodiment the
respective method ofthe invention may also serve in depleting the first and second agent and
the competition reagent, ing ng the same.
A method according to the present invention may be d out at any
temperature at which the viability of the cell population is at least essentially uncompromised.
When reference is made herein to conditions that are at least essentially not harmful, not
ental or at least essentially not compromising viability, conditions are referred to, under
which the percentage of the population of cells that are to be expanded with fiill viability, is at
least 70 %, including at least 75 %, at least 80 %, at least 85 %, at least 90 %, at least 92 %,
at least 95 %, at least 97 %, at least 98 %, at least 99 % or at least 99.5 %. In some
embodiments a method according to the invention is carried out at a temperature of about 20
°C or higher. ing on the cell population to be expanded a suitable temperature range
may for instance be from about 20 0C to about 45 °C, including from about 25 °C to about 40
°C, or from about 32 CC to 37 CC. In some embodiments a method according to the invention
is carried out at a constant temperature value, or at a selected temperature value i about 5 0C,
i about 4 CC, i about 3 0C, i about 2 CC, i about 1 °C or i about 0.5 °C. The person skilled in
the art is able to empirically determine a suitable temperature, taking into account the nature of
the cells and the ion conditions. Typically human cells are expanded at a temperature
such as 37 °C.
In a further embodiment, the invention provides an in vitro-method of expanding
a population of cells, comprising contacting a sample comprising a population of cells with a
multimerization reagent, n the multimerization reagent is in a soluble form and has
immobilized thereon (bound o) a first agent that provides a primary activation signal to
the cells. The multimerization reagent comprises at least one binding site Zl for the binding of
the first agent, wherein the first agent comprises at least one binding r Cl, wherein the
binding partner Cl is able of binding to the binding site Z1 of the multimerization t. The
first agent is bound to the multimerization reagent via the bond formed between the binding
partner Cl and the g site Z1, and the first agent binds to a receptor molecule on the
e of the cells, thereby providing a primary activation signal to the cells and thereby
activating the cells. It is expressly noted here that when a soluble multimerization agent is
used, the bond between the binding part C1 and the binding site Zl does not need to be
reversible.
[0084] In an embodiment of this second the multimerization agent has immobilized
thereon (bound thereto) a second agent that ates an accessory molecule on the surface of
the cells, wherein the second agent comprises a binding partner C2, wherein the binding
partner C2 is able of being bound to a binding site Z2 of the multimerization reagent. The
second agent is bound to the erization reagent via the bond formed between the binding
partner C2 and the binding site Z2, wherein the second agent binds to the accessory le
on the surface on the surface of the cells, thereby stimulating the activated cells.
In one embodiment of this second method, the bond formed between the binding
partner C1 and the g site Z1 may be irreversible and/or also the bond formed between
the binding r C2 and the binding site Z2 may be irreversible.
[0086] In a different embodiment of this second method, the bond formed between the
binding partner Cl and the binding site Zl may be reversible. Also the bond formed between
the binding partner C2 and the binding site Z2 may be ible. In this case, the dissociation
constant (Kd) for the reversible binding between said g site 21 and said binding partner
C1 and/or for the reversible binding between said binding site Z2 and said binding partner C2
may be in the range of 10'2 M to 10'13 M.
In this second method that is based on a soluble multimerization reagent, the first
and second reagent as well as the multimerization reagent and all other ts and cell
populations can otherwise be used in the same manner as disclosed above for the method that
makes use of reversible between the first or second agent and the multimerization reagent.
The invention further provides a reagent kit for expanding a population of cells,
the kit comprising
(i) a multimerization reagent, wherein the multimerization reagent comprises at least one
binding site Z for the reversible binding of a first agent,
(ii) a first agent that binds to a receptor molecule on the surface of the cells, thereby providing
a primary tion signal to the cells and y activating the cells, n the first agent
comprises at least one binding partner C l , wherein the binding partner Cl is able of reversibly
binding to a binding site Zl of the multimerization reagent, wherein the first agent is bound to
the multimerization reagent via the reversible bond formed between the binding partner Cl
and the binding site Z1, and
(iii) a second agent that ates an accessory molecule on the surface of the cells, wherein
the second agent comprises a binding partner C2, wherein the binding partner C2 is able of
reversibly binding to a binding site Z2 of the multimerization reagent, wherein the second
agent is bound to the erization reagent via the bond formed between the binding r
C2 and the binding site ZZ, n the second agent binds to the ory molecule on the
surface on the surface of the cells, thereby stimulating the activated cells.
The invention also provides a reagent kit for expanding a population of cells, the
kit comprising
(i) a multimerization reagent, wherein the erization reagent is in soluble form and
ses at least one binding site Z for the reversible binding of a first agent,
(ii) a first agent that binds to a receptor molecule on the surface of the cells, thereby providing
a primary tion signal to the cells and thereby activating the cells, wherein the first agent
comprises at least one binding partner Cl, wherein the binding partner Cl is able of binding to
a binding site Z1 of the multimerization reagent, wherein the first agent is bound to the
multimerization reagent via the reversible bond formed between the g partner Cl and
the binding site 21.
This second reagent kit may further comprises (iii) a second agent that stimulates
an ory molecule on the surface of the cells, n the second agent comprises a
binding partner C2, wherein the binding r C2 is able of binding to a binding site Z2 of
the multimerization reagent, wherein the second agent is bound to the multimerization reagent
via the bond formed between the binding partner C2 and the binding site Z2.
A kit as disclosed herein is in particular used when the population of cells is a
cyte population.
In accordance with the disclosure above, the invention also provides novel
multimerization ts and novel composition comprising multimerization reagents that care
capable of expanding a population of cells. Such a multimerization reagent that is capable of
expanding a population of cells is a erisation reagent that is in soluble form and
comprises at least one binding site Zl for the reversible binding of a first agent that provides a
primary activation signal to the cells, wherein the multimerization reagent has reversibly
immobilized thereon (bound thereto) said first agent that provides a primary activation signal
to the cells; wherein the first agent comprises at least one binding partner Cl, wherein the
binding r Cl is able of reversibly binding to the at least one binding site Z1 of the
multimerization reagent, wherein the first agent is bound to the multimerization reagent via the
reversible bond formed between the binding partner C1 and the binding site Z1. It should be
noted here that such a multimerization agent can have immobilized thereon any of the first
agent that are described herein.
A multimerization reagent of the invention may further comprise at least one
binding site Z2 for the ible binding of a second agent that stimulates an accessory
le on the surface of the cells, wherein the multimerization reagent has reversibly
immobilized thereon (bound thereto) the second agent that ates an accessory molecule
on the surface of the cells, wherein the second agent ses a binding partner C2, wherein
the binding partner C2 is able of binding to the at least one binding site Z2 of the
multimerization reagent. In this embodiment the second agent is bound to the multimerization
reagent Via the bond formed between the binding partner C2 and the g site Z2.
Also in line with the disclosure given above, such a multimerization reagent is
capable of expanding a lymphocyte population or a subpopulation contained in the lympocyte
population. The lymphocyte population to be expanded may any suitable population, for
example, a B cell population, a T cell population, or a natural killer cell population. The T-cell
population may be an antigen-specific T cell population, a T helper cell population, a cytotoxic
T cell, a memory T cell, a regulatory T cell, or a natural killer T cell population. Accordingly,
in such ments of the multimerization reagent the first agent is able to stimulate a
TCIUCD3 complex-associated signal in the T cells. The first agent present in the
multimerization reagent may thus be binding reagent that specifically binds CD3, while the
second agent that binds the accessory le may be a binding agent that specifically binds
CD28 or CD137.
In embodiments of the multimerization reagent the first agent that specifically
binds CD3 may be an D3-antibody, a divalent dy fragment of an anti-CD3
antibody, a monovalent antibody nt of an anti-CD3-antibody, and/or a proteinaceous
CD3 binding molecule with antibody-like binding properties. In these embodiments, the
second agent that specifically binds CD28 or CD137 may be an anti-CD28-antibody, a
divalent antibody fragment of an anti-CD28 antibody, a monovalent dy fragment of an
anti-CD28-antibody, a naceous CD28 binding molecule with antibody—like binding
properties, an anti-CD137-antibody, a divalent antibody fragment of an anti-CD137 antibody,
a monovalent dy fragment of an anti-CD137-antibody, a proteinaceous CD137 binding
molecule with antibody—like binding properties, 4-1BB ligand, and any mixture thereof. Thus,
a multimerization reagent of the invention can generally have lized thereon one kind of
first agent and a mixture of second agents, for example, an anti-CD3 antibody as first agent
and for example, an anti-CD28 antibody and 4-1BB ligand as (joint) second agents.
If the multimerization reagent is to be used for the expansion of B cells, the first
agent immobilized on the multimerization reagent may be a binding reagent that specifically
binds CD40 or CD137. In accordance with the disclosure given herein, in such embodiments
the first binding t that specifically binds CD40 or CD137 may be selected from an anti-
CD40-antibody, a divalent antibody fragment of an anti-CD40 antibody, a monovalent
dy fragment of an anti-CD40—antibody, and a proteinaceous CD40 binding molecule
with antibody-like binding ties or an anti-CD137-antibody, a divalent antibody fragment
of an anti-CD137 antibody, a monovalent antibody fragment of an D137—antibody, a
proteinaceous CD137 binding molecule with antibody-like binding properties, and CD40
ligand (CD154).
Also in accordance with the general disclosure of the present invention, in the
multimerization reagent as described herein the binding sites Z1 and Z2 of the multimerization
reagent can be identical. As described above, such a multimerization reagent may comprises
an oligomer or a r of streptavidin, an oligomer or a polymer of avidin, an oligomer or a
polymer of an analog of streptavidin that reversibly binds biotin, an oligomer or a polymer of
an analog avidin that reversibly bind biotin, a reagent that comprises at least two chelating
groups K, wherein the at least two chelating groups are capable of binding to a transition metal
ion, thereby ing the reagent capable of binding to an oligohistidine affinity tag,
multimeric glutathione-S-transferase, multimeric calmodulin and a biotinylated carrier protein.
[0098] A novel ition provided herein that is capable of expanding a population of
cells may comprise
(i) a first multimerization reagent, n the first multimerisation reagent is in soluble
form and comprises at least one binding site Z1 for the reversible binding of a first agent
that provides a primary activation signal to the cells, n the first multimerization
reagent has ibly immobilized thereon (bound thereto) said first agent that provides
a primary activation signal to the cells, n the first agent comprises at least one
binding partner C1, wherein the binding partner Cl is able ofreversibly binding to the at
least one binding site Zl of the multimerization reagent, wherein the first agent is bound
to the erization reagent Via the reversible bond formed n the binding
partner Cl and the binding site Z1 , and
(ii) a second multimerization reagent, wherein the second multimerization reagent is in soluble
form and ses at least one binding site Z2 for the reversible binding of a second agent
that stimulates an accessory le on the surface of the cells, wherein the multimerization
reagent has reversibly immobilized thereon (bound thereto) said second agent that stimulates
an accessory molecule on the surface of the cells, n the second agent comprises a
binding r C2, wherein the binding partner C2 is able of binding to the at least one
binding site Z2 of the multimerization reagent, wherein the second agent is bound to the
multimerization reagent via the bond formed between the binding partner C2 and the g
site Z2.
[0099] Such a novel composition is, for example, the reaction mixture used in Example
13, in which two separate multimerization reagents were onalized either with an uCD3
Fab fragment alone or an (xCD28 Fab fragment alone. It is noted in this context, that such a
composition was shown in Example 13 to have the same expansion efficiency as a single
multimerization reagent on which both the first agent and the second agent are jointly
lized. Thus, the combined use of two or more multimerization reagents being
functionalized individually with only one type ent (for example, one first or one second
agent) is functionally equivalent to using for the expansion one joint erization t
which has immobilized thereon both a first agent and a second agent. In this context, it is also
noted that a multimerization reagent of the present invention be functionalized with as many
agents (for example, one, two, three, four or even more agents) that are intended to be used for
the expansion of a selected cell population. A third or fourth agent may, for example, for
example provide a stimulus for the expansion of a desired ulation of cells. See in this
context, for instance, Example 13 in which a soluble multimerization reagents was reversibly
fianctionalized with three ts, namely a (1CD3 Fab fragment as first reagent, a dCD28 Fab
fragment as second reagent and a 0tCD8 Fab fragment as third reagent to enrich the
subpopulation of CD8+ T cells in a sample of a population of CD3+ T cells (lymphocyte). By
using such a combinations of agents that can all be reversibly immobilized on the same
multimerization reagent, the present invention allows for the possibility to preferentially
expand or selectively enrich any desired cell (sub)population from an sample that, for
example, comprises a variety of different subpopulations. In this context, it is noted that it
however also possible to use for this purpose use three ent multimerization reagents, for
example, a first multimerization reagent that is functionalized with only a OLCD3 Fab fragment,
a second multimerisation t that is fimctionalized with a (1CD28 Fab fragment and a third
multimerization reagent that is functionalized with a aCD8 Fab fragment. Likewise, it is
possible to use only two ent erization ts, a first multimerization reagent that
is functionalized with only a uCD3 Fab fragment and a second multimerisation reagent that is
fianctionalized with both a (1CD28 Fab nt and a (xCD8 Fab fragment. Accordingly, the
present ion allows to design any kind of wanted expansion reagent in a modular fashion.
The invention also provides an in vitro—method of serially expanding a
population of lymphocytes, wherein the population of lymphocytes comprises T cells. This
method comprises
contacting a sample comprising the T cell comprising population of lymphocytes with a
multimerization reagent,
wherein the multimerization reagent is in a soluble form and has reversibly immobilized
thereon (i) a first agent that provides a y activation signal to the T cells and (ii) a
second agent which stimulates an accessory le on the surface of the T cells,
wherein the multimerization reagent comprises at least one binding site Zl for the reversible
binding of the first agent,
n the first agent comprises at least one binding partner Cl, wherein the binding partner
C1 is able of reversibly binding to the binding site Z1 of the multimerization reagent, wherein
the first agent is bound to the multimerization reagent via the reversible bond formed between
the binding partner Cl and the binding site Z1,
wherein the multimerization reagent comprises at least one binding site Z2 for the reversible
binding of the second agent,
wherein the second agent comprises at least one binding partner C2, wherein the binding
r C2 is able of reversibly binding to the binding site Z2 of the multimerization reagent,
n the first agent is bound to the multimerization reagent via the reversible bond formed
between the g partner C2 and the binding site Z2,
wherein the first agent binds to a receptor le on the surface of the T cells, thereby
providing a primary activation signal to the cells and thereby ting the T cells,
wherein the second agent binds to the accessory molecule on the surface of the T cells, thereby
stimulating the activated cells, the first agent and the second agent thereby together inducing
the T cells to .
[00101] In this method contacting the sample that contains the population of
lymphocytes that in turn contains the T cell population with the e multimerization
reagent that has immobilized thereon the first and second agent results in specific binding of T
cells to the multimerization reagent.
The contacting of the sample comprising the T cell comprising tion of
lymphocytes with the multimerization reagent can be carried out in a bioreactor such as a
hollow-fiber bioreactor (e.g. hollow fiber bioreactor of the Quantum® cell expansion )
or a plastic bag ctor (e.g. Cellbag® used in Xuri Cell Expansion System W25 from GE
Healthcare).
This method further comprises contacting the population of lymphocytes
(reaction mixture containing the T cells bound to the multimerization reagent via the first agent
and the second agent) with (i) a free first binding partner C1 or an analogue thereof capable of
ting the bond between the first binding partner Cl and the binding site Z1 and (ii) a free
second binding partner C2 or an analogue thereof, capable of disrupting the bond n the
second binding partner C2 and the binding site Z2. By so doing the reversible bond between
said g partner C1 of the first agent and said binding sites Zl as well as the reversible
bond between said binding partner C2 of the second agent and said binding site Z2 of said
multimerization reagent is disrupted, thereby releasing in an eluate the T cells bound to the
multimerization reagent via the first agent and the second agent and ng the expansion of
the T cells.
[00104] In this method the eluate (the reaction mixture in which the expansion reaction
has been terminated by addition ofthe free first partner(s) or analogue(s) thereof) that contains
the expanded T cell population may be exposed to chromatography on a suitable (first)
stationary phase. The (first) stationary phase may be a gel filtration matrix and/or an affinity
chromatography matrix as described in International patent application WO 24474.
This gel filtration and/or affinity tography matrix comprises an affinity reagent,
wherein the affinity reagent comprises a binding site Zl and/or Z2 specifically binding to the
binding partner Cl and/or C2 comprised in the first agent or the second agent. By so doing the
first agent, the second agent, the first binding partner Cl and/or the free second binding r
C2 are immobilized on the stationary phase. In this method, the first stationary phase is fluidly
connected to the bioreactor.
In one of the embodiments of this serial expansion the binding sites Z1 and Z2
of the erization agent are identical. In addition, a single multimerization agent may be
used. When a soluble multimerization agent is used, the T cell population (or the ed cell
tion in general) is separated from the soluble multimerization reagent. The
tion/removal might be carried out using a second stationary phase. For this purpose, a
mixture comprising the T cells and the soluble multimerization reagent are exposed, before or
after being applied onto the first stationary phase described above, to chromatography on a
le second stationary phase. This ary stationary phase may be a gel filtration matrix
and/or affinity chromatography matrix, wherein the gel filtration and/or affinity
chromatography matrix comprises an affinity reagent. The affinity reagent comprised on the
chromatography resin include a binding partner D that (specifically) binds to the binding site
Z1 and/or binding site Z2, if present, of the multimerization reagent, thereby immobilizing the
erization reagent on the stationary phase. If a streptavidin based multimerization agent
is used and both first and second agents have a streptavidin g peptide as binding partner
C1 or C2, the binding partner D that is comprised in the affinity reagent of this second
stationary phase can be biotin. The soluble oligomer of streptavidin or of a streptavidin mutein
that is used as multimerization reagent then binds to the biotin that is usually covalently
coupled to a chromatography matrix such as biotin-sepharoseTM that is commercially available.
In this method of serial expansion the first agent may stimulates a TCR/CD3
complex-associated signal in the T cells and the first agent may thus be a g reagent that
specifically binds CD3. In addition, the accessory molecule on the T cell may be CD28. In this
case the second agent that binds the accessory molecule is a binding reagent that specifically
binds CD28.
In this method of serial expansion, the T cells may be transfected either during
or after expansion e. g. with a T cell or (TCR) or a chimeric antigen receptor (CAR, also
known as artificial T cell receptor). This transfection for the introduction of the gene of the
desired receptor can be carried out with any suitable retroviral vector, for example. The
genetically modified cell population can then be liberated from the initial stimulus (the
CD3/CD28 us, for example) and subsequently be stimulated with a second type of
stimulus e. g. via the de novo introduced receptor). This second type of stimulus may comprise
an antigenic stimulus in form of a peptide/MHC le, the cognate (cross-linking) ligand
ofthe genetically uced receptor (e.g. natural ligand of a CAR) or any ligand (such as an
antibody) that directly binds within the framework of the new receptor (e.g. by recognizing
nt s within the receptor). Cf in this respect, Cheadle et al, “Chimeric antigen
ors for T—cell based therapy” Methods Mol Biol. 2012; 5-66 or Barrett et al.,
ic n Receptor Therapy for Cancer Annual Review of Medicine Vol. 65: 333—347
(2014).
[00108] In this method, the population of lymphocytes that comprises T cells can be a
population of peripheral blood mononucleated cells (PBMC) or a population of enriched or
purified T cells. The population of lymphocytes may, for example, be derived from whole
blood, or from a non-mobilized apheresis t or a frozen tissue preparation.
In this method of serial ion that is based on a soluble multimerization
reagent, the first and second reagent as well as the multimerization reagent and all other
reagents and cell populations can otherwise be used in the same manner as disclosed above for
the method that makes use of reversible between the first or second agent and the
multimerization reagent.
The invention is further directed to an arrangement of a bioreactor and a first
stationary phase for chromatography. The bioreactor is suitable for the ion of cells, and
the stationary phase is suitable for cell separation and removal of reagents. The first nary
phase is a gel filtration matrix and/or affinity chromatography matrix, wherein the gel filtration
and/or affinity chromatography matrix comprises an affinity reagent, wherein the affinity
reagent comprises a binding site Zl specifically g to a binding partner Cl comprised in a
first agent and/or the affinity reagent comprises a binding site Z2 specifically binding to a
binding partner C2 comprised in a second agent. The first stationary phase is y being
suitable of immobilizing thereon the first agent and/or the second agent, the first binding
partner Cl and/or the free second binding partner C2. In addition the bioreactor and the
stationary phase are fluidly connected. This arrangement can be used in the serial expansion as
explained above and can be ated into known cell ion systems such as the
Quantum® cell expansion system) or the Xuri Cell Expansion System W25.
[00111] In this arrangement the first stationary phase is either comprised in a
tography column or is a planar stationary phase. The ement may further
comprises a second stationary phase which is fluidly connected to the first stationary phase.
The secondary stationary phase may be a gel filtration matrix and/or affinity chromatography
matrix, wherein the gel filtration and/or affinity chromatography matrix comprises an y
reagent. This affinity reagent may comprise a binding partner D that (specifically) binds to the
binding site Z1 of the erization reagent, thereby being suitable of immobilizing the
multimerization reagent on the nary phase.
The invention is further ed to an apparatus for ation and expansion
of a population of cells, the apparatus comprising at least one arrangement of a bioreactor and
a first stationary phase or a second stationary phase for chromatography as defined above.
The apparatus may further comprise a plurality of arrangements of a bioreactor
and a stationary phase being fluidly connected in series.
The apparatus may comprise a sample inlet being fluidly connected to the
bioreactor of the arrangement of a bioreactor and the stationary phase for tography. The
apparatus may also comprise a sample outlet for purified and expanded target cells, the sample
outlet being fluidly connected to the stationary phase of the last of the at least one ement
of a bioreactor and the stationary phase for chromatography.
Finally, the apparatus may be designed as a onally closed system.
As one of ordinary skill in the art will readily appreciate from the disclosure of
the present invention, other compositions of matter, means, uses, methods, or steps, presently
existing or later to be developed that perform substantially the same function or e
ntially the same result as the corresponding exemplary embodiments described herein
may likewise be utilized according to the present invention.
Experimental Examples
Example 1: Stimulation/expansion of CD3+ T responder cells with aCD3/aCD28 Fab
fragments that were reversibly immobilized on beads coated with the streptavidin mutein
Strep-tactin®.
[00117] 300.000 CD3+CD62L-responder T cells , isolated by serial
magnetic enrichment from a non-mobilized donor apheresis product) were labeled with 3uM
CFSE and stimulated with Sul of a 15ul ation of Streptactin® beads (10 mg magnetic
particles/ml, loaded with 35 ug Streptactin®/mg beads) either loaded with 0.5 ug (xCD3 Fab
fragment alone, 0.5 ug (1CD28 Fab fragment alone or a mixture of 0.5 ug (xCD3 Fab fragment
and 0.5 ug (XCD28 Fab.
The dCD3 Fab fragment used was d from the CD3 binding
monoclonal antibody produced by the hybridoma cell line OKT3. The hybridoma cell line
OKT3 and the OKT3 antibody are described in US Patent 4,361,549, the cell line has been
deposited under accession number ATCC® CRL-8001TM). The CD28 Fab used was derived
from the monoclonal anti—human CD28 antibody CD283 (Vanhove et al, BLOOD, 15 July
2003, Vol. 102, No. 2, pages 564-570). The nucleotide sequence of the variable domains of
this antibody CD283 has been deposited in GenBank in the form of a synthetic single chain
Fv construct anti-human CD28 antibody scFv28.3 under GenBank accession number
AF451974.1).
[00119] Both Fab fragments were recombinantly produced in E. coli as
bed in International patent applications WO2013/011011 and ng
as nt domains (CH1 and Ckappa) an IgGl consensus sequence. The heavy chain of both
Fab nts was carboxy-terminally fused with a sequential arrangement of two avidin
g modules (SAWSHPQFEK(GGGS)2GGSAWSHPQFEK, (SEQ ID NO: 07)), that is
commercially available as “Twin-Strep-tag® from IBA GmbH, Gottingen, Germany). The
(xCD3 Fab fragment was used as first agent with the streptavidin binding e serving as
binding partner C 1 and the (XCD28 Fab fragment was used as second agent with the
streptavidin binding peptide serving as g partner C2. The (tetrameric) streptavidin
mutein “Strep-tactin® serves as multimerization reagent on which both Fab fragments were
reversibly lized.
In the expansion experiment, Tresp cells stimulated with blank beads
(no Fab) served as negative control. Tresp cells were seeded in ts in 48-well plates along
with 300.000 CD3 cells autologous feeder cells (irradiated with 30Gy) in 3ml complete cell
culture medium (RPMI ) supplemented with 10% (v/v) fetal calf serum, L-glutamine, b-
mercapto ethanol, HEPES, penicillin, streptomycine and gentamycine) supplemented with
10U/m1 interleukin 2 (IL-2). The cells were incubated at 37°C without media exchange and
analyzed after 4 days by FACS analysis. FACS ng and analysis was done after 10min
incubation with 100uM D-biotin. One representative plot for each condition is shown in Fig.
4. Plots show live CD3+ cells that were stained with propidium iodide (PI) for live/dead
discrimination. Fig. 4a is a histogram showing size-distribution (forward scatter) of stimulated
cells. Fig. 4a shows that a specific cell population ofTresp cells was stimulated and expanded
(increase in size/number compared to the unstimulated “beads only” control) when incubated
in the presence of beads on which a mixture of 0.5 ug aCD3 Fab fragment and 0.5ug (1CD28
Fab was immobilized, after being stimulated in vitro with 0tCD3/0tCD28 Fab fragments that
were reversibly lized on beads coated with the avidin mutein Strep-tactin®. Fig.
4B depicts histograms of the dilution of the proliferation dye CFSE representing the degree of
proliferation ing to the number of cells per cell division (indicated on top of Fig. 4B, 0
represents undivided cells; 5 represents cells that have gone through at least 5 divisions). It can
be seen from Fig. 4B that the tion of T cells stimulated with the beads on which a
mixture of 0.5ug aCD3 Fab fragment and 0.5ug aCD28 Fab was lized have mostly
gone through three cell divisions and ent a more uniform proliferation pattern than with
a single stimulus alone (small number of cells within the undivided peak “0”). The increased
absolute amount of proliferation (more cells have proliferated uniformly after 4d stimulation
with aCD3 and aCD28 fimctionalized beads) is also ented by a more intense
consumption of media as depicted by a indicator color change to yellow in Fig. 4C.
Example 2: Analysis of the differential intracellular calcium mobilization in Jurkat cells
Real-time low-cytometric analysis of the differential intracellular
calcium mobilization induced in Jurkat cells that are either labeled with the aCD3 antibody
clone OKT3 or with Fab nts of OKT3 being multimerized with Strep-tactin® was
examined here.
[00122] For this purpose, Jurkat cells were loaded with the calcium-sensitive dye
Indo-l-AM and calcium e was triggered by ion of either (xCD3 monoclonal
antibody OKT3 (produced by the hybridoma cell line OKT3, see above, black squares) or
(xCD3 Fab fragments (derived from the parental cell line OKT3) that were multimerized by
reversible binding of its avidin binding peptide to soluble Strep-Tactin fluorescently
conjugated with phycoerythrin. In the case of the intact multimeric OKT3 Fab-Strep-Tactin
complexes, the calcium release was triggered over an identical time period as with the parental
antibody clone (dark grey les). Activation of cells could be completely avoided by
injection of D-biotin d, pre-dissociated Fab-Strep-Tactin complexes (light grey circles)
identical to injection of the PBS negative control (inverted white triangles). Application of
ionomycine served as positive control for calcium influx. Time-resolved changes in
intracellular Ca2+ concentration were monitored by flow-cytometry based on the change in
FL6/FL7 ratio. It can be seen from Fig. 5A that both the parental antibody OKT3 as well as the
erized monovalent Fab fragment of OKT3 effected calcium release, meaning that the
multimerized monovalent Fab nt of OKT3 is essentially as nal as the parental
antibody. Notably, the eric OKT3 Fab fragment was not able to trigger calcium release
if biotin was added to Strep-tactin on which the OKT3 Fab fragment was lized prior to
the addition of the Streptactin—OKT3 Fab fragment. In this case, the biotin disrupted the
reversible bond formed between Strep-tactin as multimerization agent and the OKT3 Fab
fragment. The monovalent Fab fragment was ore displaced from the multimerisation
agent and after dissociation was not able to trigger calcium release by binding to CD3 of the
Jurkat cells.
] In the experiments shown in Fig. 5B indo-l-AM-labeled Jurkat cells
were activated by OKT3 derived uCD3 Fab—Strep-Tactin—complexes as described in Fig. 5a.
Injection of intact (upper graph) or pre-dissociated complexes (lower graph) served as positive
or negative controls respectively. In on, stimulation of cells with intact Fab-Strep Tactin—
complexes followed by subsequent injection of D-biotin (near the peak activation at t=l40s)
resulted in abrupt disruption of aCD3 Fab—multimer signaling e graph). Injection of
ionomycine into the pre-dissociated Fab complex group served as positive control. Data are
entative of three ent experiments. Importantly, Fig. 5B shows that the addition of
D—biotin to the sample rapidly displaces the Fab fragment from the Strep-tactin
multimerization agent, thereby ively terminating the calcium release even under ongoing
calcium stimulation and demonstrating that the dissociated OKT3 Fab fragment is not any
longer biologically active. Likewise, the multimeric OKT3 Fab fragment was also not able to
trigger calcium release when biotin was added to the Strep-tactin—OKT3 Fab fragment
er prior to the addition of the Streptactin—OKT3 Fab sample to the Jurkat cells.
Example 3: Reversible staining of cells by CD3 Fab-multimers
This Example examines the reversible staining of cells by CD3 Fab-
ers. Freshly isolated PBMCs were stained with either the uCD3 monoclonal antibody
clone OKT3 (left dot plot, parental clone for the Fab-multimers) or e rythrine
(PE)—labeled OKT3 Fab-multimers and ed either before (second left column) or after
treatment with D-biotin (middle column). Remaining Fab monomers were then detected after
subsequent washing steps using fresh PE—labeled Strep-Tactin® (second right column).
Secondary Fab-multimer staining of reversibly stained cells served as control (right column).
Only live CD3 cells which are negative in staining with propidium iodide (PI) for live/dead
discrimination are shown in Fig. 6. Numbers in dot plots indicate the percentage of cells
within gates. This experiment shows that the staining of CD3+ PBMCs with an anti-CD3 Fab
fragment multimerized with Streptactin as multerization reagent is fully ible by addition
of D-biotin and that the monovalent Fab fragment alone does not bind to the CD3 molecule
present on PBMCs.
Example 4: Reversible isolation of cells by CD28 Fab-multimers
[00125] This Example shows the ion of cells by reversible binding of anti-
CD28 Fab fragments multimerized with Strep-Tactin® magnetic particles (the magnetic
les are ble from IBA GmbH Gottingen, Germany). The Fab fragments derived
from the antibody CD283 described in Example 1 above were used for this purpose. CD28+
cells were selected/isolation by Fab-multimer magnetic cell selection from freshly ed
PMBCs as ially described in International Patent Application W02013/011011. Before
selection cells were control d with either the cognate fluorescent uCD28-multimers (left
dot plot) or with an antibody directed against the immunoglobulin kappa light chain (second
left dot plot, ct-lg kappa mAb) as a control staining. After selection, CD28+ cells were treated
with D-biotin and subsequently washed to remove magnetic beads and Fab-monomers.
Liberated CD28+ cells were subsequently (re-) stained either with CD28 Fab—multimers
(second right dot plot) or with the (x-ngappa mAb (right dot plot) to detect potentially
remaining Fab-monomers. Only live (PInegative) CD3+ cells are shown. Numbers in dot plots
indicate the tage of cells within gates. Fig. 7 shows that CD28+ cells can be isolated
from PMBC using such multimerized anti-CD28 Fab fragment and that all isolation reagents
including the anti CD28 Fab-monomers can be removed after ion.
Example 5: Stimulation/expansion of CD3+ T responder cells with aCD3/aCD28
Fab fragments that were reversibly immobilized on soluble Strep-tactin
In this example CD3+ T responder cells (isolated by magnetic selection from a
sample of fresh PBMCs obtained from a Ficoll gradient) were expanded after in vitro
stimulation with (xCD3/0LCD28 Fab fragments that were reversibly immobilized on soluble
oligomeric Strep-tactin® acting as a soluble erization t. The oligomeric Strep-
® was obtained by polymerizing Strep—tactin® with sulfo SMCC (sulfosuccinimidyl 4-
(N-maleimidomethyl)cyclohexanecarb0xylate, product # 22122 Thermo Scientific) and
iminothiolan (product # 26101 Thermo ific) according to the protocol of the
manufacturer (Thermo ific). The oligomeric streptavidin were separated from
ric (unreacted) and dimeric streptavidin mutein by size exclusion chromatography and
the so obtained fraction of the eric streptavidin mutein (n2 3) was used as soluble
multimerization reagent.
For the in vitro expansion, 300.000 CD3+ responder T cells (Tresp) were
labeled with 2uM Carboxyfiuorescein imidyl ester (CFSE) and stimulated with varying
amounts of a preparation of soluble tactin® oligomers on which a combination of the
above described 0LCD3 OKT3 Fab fragment and the uCD28 Fab nt of the antibody 28.3
(both carrying the above-mentioned Twin-Strep-tag® as streptavidin binding peptide at the
heavy chain) were immobilized. (“1x” corresponds to 3ug multimerized Streptactin
functionalized with 0.5ug of the (xCD3- and 0.5ug (xCD28 monomeric Fab fragment, the
numbers “0.5x”, “2x” and “5x” indicate the respective n—fold amount of “1x”). Tresp cells
either left unstimulated or were stimulated with blank Strep—tactin multimers (no Fab) served
as negative controls. Tresp cells were seeded in duplicates in 48-well plates along with
300.000 CD3 negative autologous feeder cells (irradiated with 30Gy) in lml cell culture
medium supplemented with 20U/ml IL-2. Cells were incubated at 37°C without media
exchange and proliferation was analyzed according to CFSE on after 5 days by FACS
analysis. Fig. 8A shows the increase in the size distribution of proliferating cells after 5 days in
e compared to the negative controls. Fig. 8B shows that CD3+ Tresp cells were properly
stimulated and proliferated vigorously when ted with soluble oligomeric tactin®
(as compared to solid Streptactin magnetic particles in Fig.4) on which a mixture of (xCD3 Fab
and 0LCD28 Fab fragments were immobilized. The results in Fig. 8a and 8b indicate that under
these in vitro conditions most of the CD3+ T responder cells divided (2 to 5 cell divisions)
afier engagement of the surface CD28 and TClUCD3 complex with the uCD3 and orCD28 Fab
fragments that were reversibly immobilized on soluble Strep-tactin® oligomers. After in vitro
ion the soluble Fab-Strep-Tactin stimulation reagents were dissociated and removed
after D-biotin treatment. The dissociation and removal of monomeric Fab fragments was flow-
cytometrically analyzed by restaining cells with phycoerythrine label Strep-Tactin®) (ST-PE).
A representative histogram (dark grey histogram) is shown compared to the appropriate ST-PE
only negative control (light gray histogram). It can be seen from Fig. 8C that both Fab
fragments had completely dissociated and were entirely d from the expanded cells. Fig.
8D shows the absolute number of live n blue negative) cells after 5 days. The number
was counted using a Neubauer counting chamber and plotted against the respective stimulation
ion. Median cell numbers are shown in Fig. 8D; error bars indicate standard deviation
(SD). Fig. 8D shows that all which mixtures of dCD3 Fab fragments and dCD28 Fab
fragments that were immobilized on a soluble Strep-tactin multimerization reagent were
equally effective in expanding the CD3+ cells and resulted in an approx. 4-fold increase of
absolute cell numbers.
Example 6: Kinetics of proliferation of purified CD4+ and CD8+ T der cells
stimulated in vitro with reversible CD28 Fab-Streptamer multimers without
medium exchange
In this e the expansion kinetics of proliferation of purified CD4+ and
CD8+ T responder cells ) that were stimulated in vitro with dCD3/0iCD28 Fab
fragments that were reversibly immobilized soluble oligomeric streptavidin muteins were
examined. For this purpose, soluble oligomeric Strep-tactin® mutein of two different sizes
served as soluble multimerization t. The first kind of oligomeric Strep-tactin® was the
fraction of the oligomeric streptavidin mutein (n2 3) obtained in Example 5 (also referred
herein as “conventional Streptactin® backbone”, rated by the triangle symbol with the tip
on top in Fig. 13). The second kind of this oligomeric streptavidin mutein used as soluble
erization reagent was an oligomeric streptavidin mutein (n2 3) that was reacted with
biotinylated human serum albumin (also referred herein as “large Streptactin® backbone).
] In this example 500.000 purified CD4+ or CD8+ responder T cells (Tresp) were
separately stimulated with these two different Streptamer multimers as explained above, i.e.
with either the Streptactin backbone of e 5 (using a solution with a concentration of
1mg oligomeric avidin mutein/ml)) or with the large Streptactin backbones (0.1mg/ml).
3 ul of the both different backbones were either loaded with a combination of 0.5 ug of the
dCD3 and 0.5ug dCD28 Fab used in the r Examples that d a streptavidin binding
peptide SAWSHPQFEK(GGGS)2GGSAWSHPQFEK (SEQ ID NO: 07) at the C—terminus of
the heavy chain of the Fab fragment. In on, 4.5 ul of the conventional Streptactin
backbone was loaded with 0.5 ug (xCD3 Fab fragment, 0.5 ug aCD8 Fab fragment (IBA GmbH
Gottingen, that also carries at the C-terminus of the Fab nt the streptavidin binding
peptide SAWSHPQFEK(GGGS)2GGSAWSHPQFEK (SEQ ID NO: 07) and 0.5ug uCD28
Fab fragment. Untreated mulated) Tresp cells served as negative control and Tresp cells
stimulated with commercially available Dynabeads (beads on which 0tCD3 and 0tCD28
monoclonal antibodies are irreversible immobilized) as positive control. Tresp cells were
seeded in duplicates in 48-well plates in lml cell culture medium (RPMI 1640 (Gibco)
supplemented with 10% (V/v fetal calf serum, 0.025% (w/V) L-glutamine, 0.025% (w/V) L-
arginine, 0.1% (w/V) HEPES, 0.001% (w/v) gentamycine, 0.002% (w/V) streptomycine,
0.002% (w/v) peniciline) supplemented with 30U/ml IL-2. Cells were ted at 37°C
without media exchange and cell count was analyzed after 1, 3 and 6 days. In the experiments
of Fig. 13 the expansion was carried out without medium ge. The results for the CD4+
T responder cells are shown in Fig.13A, the results for the CD8+ T der cells are shown
in Fig. 133, with the graphs representing degree of eration according to the number of
cells harvested per time point for CD4+ Tresp (Fig. 13A) and for CD8+ Tresp in Fig.13B.
As can be seen from Fig. 13A the er” soluble multimerization reagent on
which (xCD3 and (xCD28 Fab fragments were reversibly immobilized provided for the same
amount of expansion of CD4+ T cells as Dynabeads (which are so far the standard t for
the expansion of T cells), while the r” oligomeric soluble streptactin provided for even
better expansion compared to Dynabead. This improvement might be caused by the soluble
“larger oligomeric multimerization reagent” being able to bind to more T cells at the same
time than the “smaller” e oligomer, thereby being able to stimulate more CD4+ T cells
than the “smaller” oligomer.
AS evident from Fig. 133, using the soluble multimerization reagents of the
present invention CD8+ T cells could be expanded within the first 3 days at least as efficiently
as with Dynabeads. Notably, in this time period, the expansion experiment that used a soluble
multimerization reagent that in addition to (xCD3 and (xCD28 Fab fragments (as first and
second agent) carried reversibly immobilized thereon orCD8 Fab fragment, showed the best
degree of expansion under these culturing conditions. This indicates that it is possible by using
a stimulus that is specific for a particular sub-population of cells (here the orCD8 Fab fragment)
to increase or modulate the selectivity of the expansion, thereby being able to obtain larger
s of a d cell (sub)—population.
Thus, summarizing the above, Example 6 shows that the functionality of the
soluble multimerization reagent used in the t invention in terms of triggering expansion
of T cells is comparable to the current standard methodology of using Dynabeads for this
e. However, since the stimulation can be controlled (and terminated, if wanted) by
adding a competitor such as biotin in the case of a avidin based reversible interaction
between the first and second agent and the multimerization reagent, the present invention
provides a significant advantage over the ads technology since the ion
conditions can be optimized (it would for example be possible to stop the stimulation in the
experiment of Fig.13B after 3 days). In addition, since the soluble multimerization reagent can
be easily removed from the reaction (for example, by immobilizing the reagent on a
biotinylated column after the expansion reaction), the expansion method of the ion can
be carried out and automated in closed systems that are, for example, needed for GMP
production of cells for therapeutic es, t having to deal with the removal of beads
such as Dynabeads.
Example 7: Kinetics of proliferation of purified CD4+ and CD8+ T responder cells
stimulated in vitro with reversible aCD3/aCD28 Fab-Streptamer multimers with
medium exchange
[00133] Also in this example the expansion cs of proliferation of purified CD4+
and CD8+ T responder cells (Tresp) that were stimulated in vitro with dCD3/0tCD28 Fab
fragments that were reversibly immobilized on e oligomeric streptavidin muteins were
examined. For this purpose, soluble oligomeric Strep-tactin® mutein of two different sizes
served as soluble multimerization reagent. The first kind of oligomeric Strep-tactin® was the
fraction of the oligomeric streptavidin mutein (n2 3) obtained in Example 5 (also ed
herein as “conventional Streptactin® backbone”, illustrated by the triangle symbol with the tip
down in Fig. 13). The second kind of this oligomeric streptavidin mutein used as soluble
multimerization reagent was obtained by reacting the oligomeric Strep-tactin (n2 3) obtained
in Example 5 with biotinylated human serum albumin. This soluble eric
multimerization reagent is also referred herein as “large Streptactin® backbone.
In this example, 400.000 purified CD4+ or CD8+ responder T cells (Tresp)
were separately stimulated with these two different Streptamer ers as explained above,
i.e. with either the Streptactin backbone of Example 5 (1.0 mg/ml) or with the large Streptactin
backbones (0.1mg/ml). 3ul of both the different backbones were either loaded with a
combination of 0.5 ug aCD3 and 0.5ug 0LCD28 Fab fragments described above. In addition,
4.5 ul of the Streptactin backbone of e 5 was loaded with 0.5 ug dCD3, 0.5 ug (1CD8
Fab and 0.5ug 0LCD28 Fab fragment as described above. Untreated (unstimulated) Tresp cells
served as negative control and Tresp cells stimulated with Dynabeads (on which dCD3 and
(1CD28 onal antibodies are rsible immobilized) as positive l. Tresp cells
were seeded in duplicates in 48-well plates in lml cell culture medium supplemented with
30U/m1 IL-2. Cells were incubated at 37°C with media exchange on day 3 and cell count was
analyzed after 1, 3 and 6 days. The results for the CD4+ T responder cells are shown in
A, the results for the CD8+ T der cells are shown in Fig. 143, with the graphs
representing degree of proliferation according to the number of cells harvested per time point
for CD4+ Tresp (Fig. 14A) and for CD8+ Tresp in Fig.14B.
[00135] As can be seen from Fig. 14A the soluble multimerization ts of the
present invention on which (xCD3 and dCD28 Fab fragments were reversibly immobilized
provided for better expansion of CD4+ T cells than Dynabeads.
] As evident from Fig. 14B, using the soluble multimerization reagents of the
present invention CD8+ T cells could be expanded within the first 6 days at least as efficiently
as with Dynabeads. Notably, in this time period, the expansion experiment that used the larger
soluble multimerization reagent that carried (XCD3 and (xCD28 Fab fragments (as first and
second agent) showed the best degree of expansion under these culturing conditions. This
might again be caused by the soluble “larger oligomeric erization reagent” being able to
bind to more T cells at the same time than the “smaller” soluble oligomer, thereby being able
to stimulate more CD4+ T cells than the “smaller” oligomer.
Example 8: ion kinetics of purified CD4+ and CD8+ T cell cultures with or
without medium exchange
In this Example the combined data from Examples 6 and 7 were normalized on
input cell number for the er” soluble multimerization reagent and positive and negative
control. No normalization data was obtained on the “larger” erization reagent. As
explained in Examples 6 and 7, 400.000 to 500.000 CD4+ or CD8+ responder T cells (Tresp)
were stimulated with 3ul of a preparation of Streptactin multimers (1mg/ml; on which 0.5ug
uCD3 Fab fragment and 0.5 ug uCD28 Fab fragment were lized. Untreated
mulated) Tresp cells served as negative control and Tresp cells stimulated with
Dynabeads as positive control. Tresp cells were seeded in duplicates in 48-well plates in lml
cell culture medium supplemented with 30U/ml IL-2. Tresp cells were seeded in duplicates in
48-well plates in lml cell culture medium mented with 30U/ml IL-2. Cells were
incubated at 37°C with media exchange (straight lines in Fig. 15) or without media exchange
(dashed lines in Fig. 15) on day 3 and cell count was analyzed after 1, 3 and 6 days. As evident
from the normalized data of Fig. 15A, the “smaller” soluble multimerization reagent on which
uCD3 and uCD28 Fab fragments were reversibly immobilized yielded an about 2.5 fold
ion of CD4+ T cells, while the expansion using Dynabeads yielded an about 1.8 fold
ion rate. Thus, the use of a soluble multimerization reagent of the invention even
provides for an improvement in the expansion of CD4+ T cells over Dynabeads. Similarly,
Fig. ISB, confirms that using the soluble erization reagents of the present invention
CD8+ T cells could be expanded within the first 3 days at least as efficiently as with
Dynabeads.
Example 9: Early cluster ion after activation of d CD4+ and CD8+ T
responder cells stimulated in vitro with ible aCD3/aCD28 Fab-Streptamer
multimers
[00138] In this Example, 400.000 CD4+ or CD8+ responder T cells (Tresp) were
stimulated with 3u1 of a preparation of oligomeric actin multimerization reagent
(1mg/ml) loaded with a ation of 0.5ug uCD3- and 0.5ug uCD28 Fab. Untreated
(unstimulated) Tresp cells served as negative control and Tresp cells stimulated with
Dynabeads as positive l. Tresp cells were seeded in duplicates in 48-well plates in lml
cell culture medium supplemented with 30U/ml lL-2. Cells were incubated at 37°C and
microscopically analyzed after 1 and 2 days. Stimulation ofCD4+ Tresp (Fig. 16A) and CD8+
Tresp (Fig. 16B) are shown for Dynabeads (middle row) and Streptamer multimers (lower
row) respectively. The photographs represent degree of cluster formation: For better visibility
exemplary clusters are indicated by circles for the stimulation with soluble streptavidin mutein
ers in Fig. 16A and Fig. 16B. Clusters within the Dynabead stimulation are readily
visibly by accumulation of dark stimulatory particles. As evident, both for CD4+ and CD8+ T
cells early clusters formed when using the expansion method of the invention that employs a
e oligomeric multimerization reagent.
Example 10: Expansion kinetics & phenotype of polyclonal
activated/expanded bulk CD3+ central memory T cells (Tcm)
] In this Example, 500.000 CD3+CD62L+CD45RA- responder Tcm cells (Tresp)
were stimulated with 3u1 of a preparation of the soluble eric Streptactin of Example 5
l) that was either loaded with a combination of 0.5ug (xCD3 and 0.5 ug aCD28 Fab.
Furthermore, 4.5 ul of a ation of Streptactin multimers loaded with 0.5ug uCD3, 0.5 ug
uCD8 Fab and 0.5ug uCD28 Fab was used as an additional stimulation condition. Untreated
(unstimulated) Tresp cells served as negative control and Tresp cells stimulated with
Dynabeads (on which (xCD3 and (xCD28 monoclonal antibodies are irreversible immobilized)
as positive l. Tresp cells were seeded in 48-well plates in lml cell culture medium
supplemented with 30U/m1 IL-2 only or 30U/m1 IL-2 and 5ng/m1 lL-lS. Cells were incubated
at 37°C with media exchange every 3 days and cell count was analyzed after 7 and 14 days.
Graphs represent degree of proliferation according to the number of cells harvested per time
point, in Fig. 17A only IL-2 supplemented media and in Fig.17B IL-2 and IL-15 supplemented
media. As can be seen from both Fig.17A and Fig. 17B, the soluble multimerization reagent
that has reversibly bound thereon CD3 Fab fragment and uCD28 Fab fragment yields better
cell expansion than the Dynabeads. As further shown by the flow-cytometric analysis of
CD62L and CD127 surface expression after 14 days of culture in variable ne milieus of
Fig. 17C, the experimental ches using soluble multimerization reagents of the present
invention retain, under both conditions chosen here, a higher content of CD127-expressing
long-lived memory T cells than expansion with Dynabeads. This illustrates a further advantage
ofthe methods of the present invention.
Example 11: Selective Antigen-specific expansion of Tcm responder cells out of bulk
CD3+ central memory T cells (kinetics & phenotype)
In this Example, the kinetics and the phenotype of selective n specific
(Ag-specific) expansion out of purified 62L+CD45RA- Tcm responder cells was
examined.
In more detail, CD3+CD62L+CD45RA— Tcm responder cells were stimulated
in vitro with both a peptideiMHC molecule complex (that acts as first agent that provides a
primary activation signal to the cells) and an OLCD28 Fab nt (that acts as second reagent
that stimulates an accessory molecule on the surface of the . Both the complex of antigen
c peptide with the MHC molecule and the (1CD28 Fab fragment were reversibly
immobilized on the soluble oligomeric avidin mutein (with n2 3) described in Example
. The peptide that was used for the antigen specific expansion was the peptide YVL
(SEQ ID NO: 06), amino acids 309—317 of the immediate-early 1 protein (described in
Ameres et al, PLOS Pathogens, May 2013, vol. 9, issue 5, e1003383) representing an HLA-
C7/IE-1 epitope that is specific for cytomegalovirus (CMV). The MHC I molecule that
presents the peptide carries at the C-terminus of the or chain (heavy chain) the streptavidin
binding peptide (SAWSHPQFEK(GGGS)2GGSAWSHPQFEK, (SEQ ID NO: 07) that is
commercially available as “Twin-Strep—tag®” from IBA GmbH, Gottingen, Germany).
For this purpose, 500.000 CD3+CD62L+CD45RA- responder Tcm cells
(Tresp) were stimulated Ag—specifically using 3 ul of a preparation of soluble oligomeric
Streptactin multimerization reagent functionalized with 0.5 ug of the peptidezMHC class I
complexes equipped with the streptavidin binding peptide and with 0.5ug of the uCD28 Fab
described above. As an ative, 4.5 ul of a of preparation of the Streptactin multimerization
reagent were loaded with 0.5ug ofthese peptide:MHC class I complexes, 0.5 ug CD8 uFab and
0.5ug uCD28 Fab. For ison, polyclonal stimulation was performed, using 3ul of a
preparation of Streptactin multimerization reagent (lmg/ml) either loaded with a combination
of 0.5 ug (xCD3 Fab and 0.5 ug 0LCD28 Fab. Again as the alternative stimulation condition
described above, 4.5 ul of a preparation of Streptactin multimerization reagent reversibly
loaded with 0.5ug uCD3 Fab, 0.5 ug (iCD8 Fab and 0.5 ug uCD28 Fab was used. Untreated
(unstimulated) Tresp cells served as negative control and Tresp cells stimulated polyclonal
with ads (beads on which uCD3 and uCD28 monoclonal antibodies are irreversible
immobilized) as positive control. Tresp cells were seeded in l plates in lml cell culture
medium mented with 30U/ml IL-2 and 5ng/ml IL-15. Cells were incubated at 37°C with
media ge every 3 days and cell count was analyzed afier 7 and 14 days. The exemplary
flow-cytometric is for the fraction of cific cells that was stimulated/expanded via
the soluble strept-tactin oligomer on which the peptide:MHC-I complex for an HLA-C7/IE-l
epitope (for CMV) was immobilized (Fig. 18A) show that these antigen-specific T cells were
specifically expanded. The graphs of Fig. 18B to Fig. 18E (that represent the degree of
expansion of distinct cificities according to the number of peptide:MHCI multimerpositive
cells harvested per time point in analogy to the expansion experiment shown in
Fig.18A) show that, the multerimerization reagent that uses the respective complex of the Ag-
specific peptide and MHC 1 le provided for the highest number of expanded cells
(ranging from an twentyfold increase in the number of cells for the Ag-specific cells that
recognize the pp65 epitope ofCMV (amino acids 341-350 (QYDPVAALF, (SEQ ID NO: 08))
restricted by 402) (see Fig. 18B) to an 98 fold increase in the number of cific
cells that recognize the HLA—B7/IE-1309_317 epitope (CRVLCCYVL (SEQ ID NO: 06)) of
CMV (see Fig. 18E), y showing that the expansion method of the present invention is
fially applicable to the expansion of Ag-specific cells. y, the exemplary flow-cytometric
analysis of CD62L and CD127 surface expression after 14 days of culture for HLA-
B7/Hexon5 epitope (for adenovirus) shown in Fig. 18F further confirms that experimental
approaches using the soluble multimerization reagents of the present invention retain a higher
content of CD127-expressing long-lived memory T cells in polyclonal and Ag-specific
stimulatory conditions.
Example 12: Selective Ag-specific expansion kinetics & phenotype of bulk central
memory T cells
This e examines the kinetics of selective Ag-specific ion out of
purified CD3+CD62L+CD45RA-Tcm responder cells that were stimulated in vitro with a)
n specific e MHC I complexes and b) aCD28 Fab fragments that were reversibly
immobilized as first and second agent on soluble oligomeric streptaVidin muteins.
For this purpose 0 CD3+CD62L+CD45RA- responder Tcm cells (Tresp)
were stimulated Ag-specifically using 3 ul of a preparation of Streptactin multimerization
reagent filnctionalized with 0.5 ug peptide:MHC class I complexes equipped with a
streptavidin binding peptide (the specific peptide represents amino acids 114-124
(CPYSGTAYNSL, SEQ ID NO: 10) of the Hexon 5 protein of adenovirus ) restricted by
HLA-B07) and 0.5ug (1CD28 Fab. As an alternative, 4.5 ul of a preparation of Streptactin
multimerization reagent loaded with 0.5 ug this peptide:MHC class I complex, 0.5 ug 0LCD8
Fab and 0.5ug (xCD28 Fab. For comparison, polyclonal stimulation was med, using 3 ul
of a preparation of Streptactin multimerization reagent (1mg/ml) either loaded with a
combination of 0.5 ug OLCD3 Fab and 0.5 ug (xCD28 Fab. Again as the alternative stimulation
ion described above, 4.5ul of a preparation of Streptactin multimers loaded with 0.5ug
dCD3 Fab, 0.5 ug dCD8 Fab and 0.5 ug dCD28 Fab was used. Untreated (unstimulated) Tresp
cells served as negative control and Tresp cells stimulated onal with Dynabeads as
positive control. Tresp cells were seeded in 48-well plates in lml cell culture medium
supplemented with 30U/ml IL-2 and Sng/ml IL-IS. Cells were incubated at 37°C with media
exchange every 3 days and cell count was analyzed after 7 and 14 days. The pictures shown in
Fig. 19 represent degree of cluster ion on day 5, exemplary Ag-specific stimulation is
illustrated for the /Hexon 5 epitope of adenovirus. As can be seen from Fig. 19, such
adenovirus antigen specific cells could be specifically expanded from the original
CD3+CD62L+CD45RA—Tcrn responder population.
Example 13: Yield and phenotype of expanded CD8+ T cells — size variation of
soluble multimerization reagent and addition of uCD8-Fab addition for ation
In this Example, the expansion of purified CD8+ T responder cells stimulated in
vitro with (xCD3/0tCD28 Fab fragments that were reversibly lized soluble eric
streptavidin muteins were examined. In addition, the effect of adding (xCD8-Fab to the
erization reagent for increasing the specificity of the expansion for CD8+ T cells was
examined.
For this purpose, 300.000 purified CD8+ responder T cells (Tresp) were
separately stimulated with two ent actin based multimerization reagents, namely
either the small oligomeric Streptactin multimerization reagent of Example 5 (lmg/ml) or the
larger Streptactin oligomers bed above (0.1mg/ml). 3ul of both different multimerization
reagent (backbones) were either loaded with a combination of the 0.5 ug dCD3 and 0.5ug
uCD28 Fab fragments described above. In addition, 4.5 ul of the smaller Streptactin
multimerization reagent (backbone) was loaded with 0.5 ug (xCD3, 0.5 ug ()tCD8 Fab and 0.5 ug
uCD28 Fab fragments described above. Furthermore 3rd of the “smaller” Streptactin
multimerization reagent (backbone) only nalized with 0.5ug dCD3 Fab nt alone
or 0.5 ug dCD28 Fab fragment alone was used. Unstimulated Tresp cells served as negative
control and Tresp stimulated with Dynabeads served as positive control. Tresp cells were
seeded in duplicates in 48-well plates in lml cell culture medium supplemented with 30U/ml
IL—2. Cells were incubated at 37°C with media exchange after 3 days and analyzed after 6
days. Fig. 20A depicts the degree of proliferation according to the number of cells harvested at
day 6 compared to the negative controls and normalized to the positive control. Fig. 20A
shows that the expansion of the CD8+ T cells using the e multimerization reagents of the
invention result in higher yields of the CD8+ T cells than expansion using dynabeads. The
FACS analysis of CD8 surface expression (Fig.20B) and CD45RO surface expression (Fig.
20C) after cell culture shows that the same phenotype of CD8+ T cells were expanded by
either the multimerization ts of the invention or ads (the various stimulating
conditions were compared using one-way ANOVA and no significant ence (n.s.) was
detected). The improved yield of the CD8+ cells using the inventive expansion methods
compared to the Dynabeads might be due to the fact that the soluble multimerization reagent
can access their target ors on the cell surface better than the antibodies that are
immobilized on the ads. This improved yield might become very advantageous when
expanding rare population of cells from an initial sample.
In addition, comparing the yield of expansion achieved with the
multimerization agent on which both the 0.5ug uCD3 and 0.5ug (xCD28 Fab fragments were
jointly immobilized (second column from the left in Fig. 20B) to the yield using two
multimerisation ts which were functionalized only with the (xCD3 Fab fragment alone or
the uCD28 Fab fragment alone (third column from the lefi in Fig. 20B), it can be seen that
both experiments had the same expansion efficiency. Thus, these experiments show that using
one multimerization reagent on which both the first agent and the second agent are jointly
lized is functionally equivalent to using for the expansion two separate multimerization
reagents which are loaded with only the first agent and the second agent, respectively.
e 14: Yield & phenotype of expanded CD8+ T cells — titration of separate
soluble erization reagents with different ratios of aCD3- and aCD28 Fab
nt immobilized thereon
In this Example the yield and the phenotype of expanded CD8+ T responder
cells (Tresp) that were stimulated in vitro with (XCD3/(XCD28 Fab fragments that were
reversibly immobilized in different amounts on soluble oligomeric streptavidin muteins were
examined.
[00149] For this e 300.000 CD8+ responder T cells (Tresp) were stimulated with
varying amounts of a mixture of preparations of the “small” oligomeric Streptactin
multimerization t l) fianctionalized with dCD3 Fab alone and dCD28 Fab alone
(,,1x“ corresponds to 1.5 ug actin multimerization reagent flinctionalized with 0.5ug
aCD3 alone and 1.5 ug multimerized actin functionalized with 0.5ug dCD28 Fab
fragment alone), or 3 ul of a preparation of the Streptactin multimerization reagent loaded with
0.5ug uCD3 and (10.5 ug CD28 Fab, or 4.5ul of a preparation of the Streptactin
multimerization reagent loaded with 0.5ug (xCD3, 0.5ug strep-tagged 0LCD8 and 0.5ug (xCD28
Fab. Untreated Tresp cells served as negative control and Tresp stimulated with Dynabeads as
positive control. Tresp cells were seeded in l plates in 1ml cell e medium
supplemented with 30U/ml IL-2. Cells were incubated at 37°C without media exchange and
analyzed after 5 days. Fig.21A depicts the degree of proliferation according to the number of
cells harvested at day 5 compared to the negative controls and normalized to the positive
control. Fig. 21A shows that the expansion of the CD8+ T cells using the various soluble
multimerization reagents of the invention result in higher yields of the CD8+ T cells than
expansion using dynabeads (especially the cumulative total t amount of the 5x condition
resulted in an optimal expansion of cells especially over time/increase in total cells by
beginning cell division). The FACS analysis of CD8 surface expression 13) and
CD45RO surface expression (Fig. 21C) after cell e shows that the same phenotype of
CD8+ T cells were expanded by either the various erization reagents of the invention or
by the cially available Dynabeads.
Example 15: Activation of intracellular signaling cascades after Streptamer multimers
stimulation of aCD19-CAR transduced Jurkat cells
In this Example the activation of intracellular signaling cascades of transduced
Jurkat cells that have been modified to express a tumor—specific chimeric antigen receptor
(CAR), namely here CD19 and that were ated using the oligomeric Strep-tactin® of
Example 5 as soluble erization reagent was examined.
For this purpose, 300.000 Jurkat responder cells (Jresp) were stimulated with
(A) varying amounts of a mixture of preparations of Streptactin multimerization reagent
(1mg/ml) fianctionalized with dCD3 Fab and uCD28 Fab fragments described here (,,x1“
corresponds to 3ug Streptactin multerization reagent onalized with 0.5ug dCD3— and
0.5 ug dCD28 Fab — this provides a “polyclonal Streptactin based multimerization reagent”), or
(B) 3 ul of a ation of Streptactin multimerization reagent fianctionalized with 0.5ug (x1)
or lug (x2) of the extracellular domain (ECD) of CD19 (the natural ligand for the (xCDl9-
CAR — this provides a “CAR-specific Streptactin based multimerization reagent”), or 3 ul of a
preparation of Streptactin multimerization reagent loaded with 0.5ug (x1) or lug (x2) ngG
recognizing the IgG4 spacer within the uCD19-CAR — this also provides a “CAR-specific
Streptavidin mutein based multimerization reagent). ECD of CD19 equipped with a
hexahistidine tag was obtained from Sino Biological/Life technologies (SEQ ID NO: 27) and
was functionalized for binding to the streptavidin based multimerization reagent by mixing the
ECD of CD19 with the adapter molecule REPPER (IBA GmbH, Germany, Order
number 2-0920—005) at a molecular ratio of 1:1 and incubating for 15 min at room
temperature. The His-STREPPER adapter molecule contains a chelating portion that binds to
the hexahistidine tag and a streptavidin binding peptide, thereby temporarily providing the
target molecule, here the ECD of CD19 with a streptavidin binding peptide that can reversibly
bind to a streptavidin mutein based multimerization reagent. Jresp stimulated with ads
(beads having irreversibly immobilized thereon (1CD3— and 0LCD28— monoclonal antibodies) or
PMA and Ionomycin served as positive ls. Jresp cells were seeded in 1.5ml Eppendorf
tubes in 200ul cell culture medium mented with 30U/ml IL-2. Cells were incubated at
37°C and put on ice and lysed after 0min to 20min of stimulation. Detection ofphosphorylated
ERK indicates active MAPK ing, staining of the housekeeper B-Actin indicates loading
of equal amounts of total protein per condition and time point. As can be seen from the
comparison of Fig. 22A showing tion of the Jurkat cells via the “polyclonal Streptactin
multimerization t” and Fig. 223 showing tion of the Jurkat cells Via the two
pecific Streptactin based multimerization reagents”, the Jurkat cells can be
activated/expanded via the binding of the CD19 extracellular domain to the CD19 specific
chimeric antigen receptor. Since genetic down-stream processing of T cells is almost
exclusively performed on pre-selected cell populations, a c activation via cross-linking
of uced CARS via the IgG4 spacer domain (this is ved within various CARS with
different specificities) broadens the applicability for reversible cell stimulation/expansion in
these in vitro cell-processing situations.
[00152] Thus, this experiment shows that in principle any cell population that is
activated by binding of an agent (ligand) that provides a primary activation signal to the cell
population can be expanded using a first agent reversibly immobilized on a multimerization
reagent as described here.
Example 16: Yield and subset composition of expanded CD3+ T cells with addition
of orCD8-Fab for stimulation
The experiment shows the expansion of purified CD3+ T responder cells
stimulated in vitro with CD28 Fab fragments that were reversibly immobilized on the
soluble oligomeric Strep-tactin® of Example 5 that served a e multimerization reagent.
In one ment, in addition to dCD3/dCD28 Fab fragments, also a dCD8 Fab fragment
commercially available from IBA GmbH, Gottingen, Germany (catalogue number 6
203) was immobilized on the soluble oligomer of the streptavidin mutein in order to test
whether it is possible to preferentially stimulate a specific T cell subpopulation in vitro with
the reversible aCD3/aCD28 Fab-Streptamer multimers. In more detail, 500.000 purified CD3+
responder T cells (Tresp) were stimulated with 3 ul of a preparation of oligomeric Streptavidin
(lmg/ml) loaded with a combination of 0.5 ug of the (1CD3 and 0.5 ug of the dCD28 Fab. As an
ative approach, 4.5 ul of the Streptactin oligomer were loaded with 0.5 ug dCD3, 0.5 ug
strep-tagged dCD8 Fab and 0.5 ug strep-tagged dCD28 Fab. Unstimulated Tresp cells served
as negative control and Tresp stimulated with Dynabeads (beads on which dCD3 and dCD28
monoclonal antibodies are irreversible lized) served as positive control. As can be seen
from Fig. 23A, the multimerization reagent that is reversibly loaded with the dCD3 Fab
nt, the dCD28 Fab nt and also the dCD8 Fab fragment provided the highest
number of expanded CD3+ T cells. With 1x1 x 106 the number of expanded cells the yield was
about 30 % higher than for expansion of these T cells using commercially available
Dynabeads. In addition and more important, as shown in Fig. 23B with this multimerization
t that caries the dCDS Fab fragment, the uCD28 Fab nt and the dCD8 Fab
fragment, the amount of CD8+ T cells were the highest, compared to both the expansion with
Dynabeads or a soluble multimerization reagent of the invention that caries only the dCD3 Fab
fragment and the dCD28 Fab fragment as first and second agent as described herein. Thus,
also this experiment shows the advantage of the present invention that in addition to a first
agent that es a primary tion signal to the desired cell population and optionally a
second agent that provide a mulatory signal, a further agent that is specific for the
activation of the desired cell population can be immobilized on the multimerization reagent.
Thus, by so doing, the present invention provides for the possibility to preferentially expand or
selectively enrich any desired cell (sub)p0pulation from an sample that, for example,
comprises a variety of different subpopulations.
Example 17: el Antigen-specific expansion of Tcm responder cells out of a
single pool
[00154] In this Example, the kinetics of parallel Antigen specific (Ag-specific)
expansion out of a single pool ofT responder cells ated in Vitro with multiple reversible
peptide:MHC/ uCH28 Fab-Streptamer multimers is examined.
500.000 CD3+CD62L+CD45RA- responder Tcm cells (Tresp) are
aneously stimulated for multiple Ag—specificities using for each specificity, 3ul of
Streptactin multimers functionalized with 0.5 ug of the respective peptide:MHC class I
complexes that carries a avidin binding peptide and 0.5ug uCD28 Fab that also carries a
streptavidin binding peptide. As an alternative approach, 4.5 ul of Streptactin based
multimerization reagent fianctionalized with 0.5ug peptide:MHC class 1 complexes ng a
streptavidin g peptide, 0.5 ug uCD8 Fab and 0.5 ug (1CD28 Fab as described here are
used for each city. For comparison, polyclonal stimulation is med, using 3 ul of a
preparation of Streptactin based multimerization t (lmg/ml) either reversibly loaded
with a combination of 0.5ug aCD3 Fab and 0.5ug uCD28 Fab. Again as the alternative
stimulation condition described above, 4.5 ul of a preparation of the Streptactin based
multimerization reagent reversibly loaded with 0.5 ug (xCD3 Fab, 0.5 ug uCD8 Fab and 0.5 ug
uCD28 Fab (each of them carrying a streptavidin binding peptide can be used. Untreated
(unstimulated) Tresp cells serve as negative control and Tresp cells stimulated polyclonal with
Dynabeads - and OLCD28- mAb coated beads) as positive l. Tresp cells are seeded
in 48-well plates in lml cell culture medium supplemented with 30U/ml IL-2 and Sng/ml IL-
. Cells are incubated at 37°C with media exchange every 3 days and cell count are analyzed
after 7 and 14 days.
Example 18: Preferential proliferation of CD8+ T cells among CD3+ T responder
cells stimulated in vitro with streptavidin based multimerization reagents reversibly
functionalized with aCD3/aCD8/aCD28 Fab fragments
[00156] 300.000 CD3+ responder T cells (Tresp) are stimulated with 3ul of a
preparation of Streptactin multimerization (lmg/ml) or a preparation of a multimerization
reagent using the large Streptactin backbone (0.1mg/ml) either loaded with a combination of
0.5 ug 0LCD3 and 0.5ug 0LCD28 Fab, or 4.5 ul of a preparation of Streptactin based
erization reagent loaded with 0.5 ug aCD3, 0.5 ug aCDS Fab and 0.5 ug aCD28 Fab, or
3ul of a mixture of preparations of Streptactin based multimerization reagent with 0.5 ug
(xCD3 Fab alone and 0.5 ug dCD28 Fab alone (each Fab fragment again carries a streptavidin
binding peptide). Untreated Tresp cells serve as negative control and Tresp stimulated with
Dynabeads (0LCD3- and - mAb coated beads) as positive control. Tresp cells are seeded
in duplicates in 48-well plates in lml cell e medium supplemented with 30U/ml IL-2.
Cells are incubated at 37°C with media exchange after 3 days and analyzed after 6 days.
Example 19: Preferential proliferation of CD8+ T cells among CD3+ T responder
cells stimulated in vitro with streptavidin based multimerization reagents reversibly
functionalized with (1CD3 and (1CD28 Fab fragments
300.000 CD3+ der T cells (Tresp) are stimulated with varying amounts
of a e of preparations of Streptactin based multimerization reagent (lmg/ml)
functionalized with (xCD3 Fab fragment alone and orCD28 Fab fragment alone (1.5 ug
Streptactin based multimerization reagent fianctionalized with 0.5 ug (xCD3 Fab fragment alone
and 1.5 ug Streptactin based multimerization reagent flinctionalized with 0.5 ug dCD28 Fab
fragment alone), or varying amounts of a mixture of preparations of Streptactin based
erization reagent flinctionalized with orCD3 Fab fragment and (xCD28 Fab fragment
with or without (1CD8 Fab nt (each Fab fragment again carries a streptavidin binding
peptide) (3 ug Streptactin based multimerization reagent functionalized with 0.5ug (xCD3— and
0.5ug 0LCD28 Fab nt — without (xCD8 Fab fragment, or 4.5ul of a preparation of
Streptactin multimerization t loaded with 0.5 ug (xCD3 Fab fragment, 0.5 ug 0LCD8 Fab
fragment and 0.5ug orCD28 Fab fragment, wherein Fab fragment again carries a streptavidin
binding peptide). Untreated Tresp cells serve as negative control and Tresp ated with
Dynabeads (0LCD3- and (xCD28- mAb coated beads) as positive control. Tresp cells are seeded
in l plates in lml cell culture medium supplemented with 30U/ml IL-2. Cells are
ted at 37°C with media exchange after 3 days and analyzed after 6 days.
[00158] The listing or discussion of a usly published document in this
specification should not necessarily be taken as an acknowledgement that the document is part
ofthe state of the art or is common general knowledge.
The invention illustratively described herein may suitably be practiced in the
absence of any t or ts, limitation or limitations, not specifically disclosed herein.
Thus, for example, the terms “comprising”, “including,” containing”, etc. shall be read
expansively and without limitation. Additionally, the terms and expressions employed herein
have been used as terms of description and not of limitation, and there is no intention in the
use of such terms and expressions of excluding any equivalents of the features shown and
described or portions thereof, but it is recognized that various modifications are possible within
the scope of the invention claimed. Thus, it should be understood that although the t
invention has been specifically sed by exemplary embodiments and optional features,
modification and variation of the inventions embodied therein herein sed may be resorted
to by those skilled in the art, and that such modifications and variations are considered to be
within the scope of this invention.
The invention has been described broadly and generically herein. Each of the
narrower species and eric groupings falling within the generic disclosure also form part
of the invention. This includes the generic description of the invention with a proviso or
negative limitation removing any subject matter from the genus, regardless of whether or not
the excised material is specifically recited herein.
Other embodiments are within the following claims. In on, where features
or aspects of the invention are described in terms of Markush groups, those skilled in the art
will recognize that the invention is also thereby described in terms of any dual member
or subgroup of members of the Markush group.
In a first aspect of the invention, there is provided an arrangement of a
bioreactor, a first stationary phase for tography, and a second nary phase for
chromatography, n:
(a) the bioreactor is suitable for the ion of lymphocytes using a multimerization
reagent capable of stimulating the cytes, wherein:
(i) the multimerization reagent is in a soluble form and is reversibly bound to a first
agent comprising a streptavidin-binding peptide C1 and a second agent comprising a
streptavidin-binding peptide C2, wherein the first agent binds to a receptor molecule on the
surface of the lymphocytes to provide a primary activation signal to the lymphocytes, and the
second agent binds to an accessory molecule on the surface of the lymphocytes to stimulate
an ory signal in the lymphocytes, and
(ii) the multimerization reagent comprises streptavidin or a streptavidin mutein that
reversibly binds to the streptavidin-binding peptides C1 and C2,
(b) the first stationary phase is suitable for cell separation and removal of reagents, is
sed in a first chromatography column, and is a first gel filtration matrix and/or affinity
chromatography matrix, wherein the first gel filtration and/or affinity chromatography matrix
comprises a first affinity reagent comprising avidin or a streptavidin mutein capable of
specifically g to the avidin-binding e C1 and the streptavidin-binding
peptide C2, the first affinity reagent thereby being suitable for immobilizing on the first
stationary phase the first agent and the second agent,
(c) the second stationary phase is comprised in a second chromatography column and is
a second gel filtration matrix and/or affinity chromatography matrix, wherein the second gel
tion and/or affinity chromatography matrix comprises a second affinity reagent
comprising a biotin, the second affinity reagent thereby being suitable for lizing the
multimerization t on the second stationary phase,
(d) the bioreactor and the first stationary phase are fluidly ted, and
(e) the first stationary phase and the second stationary phase are fluidly connected.
In a second aspect of the invention, there is provided an arrangement of a
bioreactor, a first stationary phase for chromatography, and a second stationary phase for
chromatography, wherein:
(a) the bioreactor is suitable for the expansion of lymphocytes using a multimerization
reagent capable of stimulating cytes, wherein:
(i) the multimerization reagent is in a soluble form and is reversibly bound to a first
agent comprising a streptavidin-binding e C1 and a second agent comprising a
avidin-binding peptide C2, wherein the first agent binds to a receptor molecule on the
surface of the cytes to e a primary activation signal to the lymphocytes, and the
second agent binds to an accessory molecule on the surface of the lymphocytes to stimulate
an accessory signal in the lymphocytes, and
(ii) the multimerization reagent comprises avidin or a streptavidin mutein that
reversibly binds to the streptavidin-binding peptides C1 and C2,
(b) the first stationary phase is suitable for cell separation and removal of reagents, is
comprised in a first chromatography column, and is a first gel filtration matrix and/or affinity
tography matrix, wherein the first gel filtration and/or affinity chromatography matrix
comprises a first affinity reagent comprising a , the first affinity reagent thereby being
suitable for immobilizing the multimerization reagent on the first stationary phase,
(c) the second stationary phase is comprised in a second chromatography column and is
a second gel filtration matrix and/or affinity chromatography matrix, wherein the second gel
filtration and/or affinity chromatography matrix comprises a second affinity reagent
comprising streptavidin or a streptavidin mutein capable of specifically binding to the
streptavidin-binding peptide C1 and the streptavidin-binding peptide C2, the second affinity
t thereby being suitable for immobilizing on the second stationary phase the first agent
and the second agent,
(d) the bioreactor and the first stationary phase are fluidly ted, and
(e) the first stationary phase and the second nary phase are fluidly connected.
Claims (13)
1. An arrangement of a bioreactor, a first stationary phase for chromatography, and a second stationary phase for chromatography, wherein: (a) the bioreactor is suitable for the expansion of lymphocytes using a erization reagent capable of stimulating the lymphocytes, wherein: (i) the multimerization reagent is in a soluble form and is reversibly bound to a first agent comprising a streptavidin-binding peptide C1 and a second agent comprising a streptavidin-binding e C2, wherein the first agent binds to a receptor molecule on the surface of the lymphocytes to provide a primary activation signal to the lymphocytes, and the second agent binds to an accessory molecule on the surface of the lymphocytes to stimulate an accessory signal in the cytes, (ii) the multimerization reagent comprises streptavidin or a streptavidin mutein that reversibly binds to the streptavidin-binding peptides C1 and C2, (b) the first stationary phase is suitable for cell separation and removal of reagents, is comprised in a first chromatography column, and is a first gel filtration matrix and/or affinity chromatography matrix, wherein the first gel filtration and/or ty tography matrix comprises a first affinity reagent comprising streptavidin or a streptavidin mutein capable of specifically g to the streptavidin-binding peptide C1 and the streptavidin-binding peptide C2, the first affinity reagent thereby being suitable for immobilizing on the first stationary phase the first agent and the second agent, (c) the second nary phase is sed in a second chromatography column and is a second gel filtration matrix and/or affinity chromatography matrix, wherein the second gel filtration and/or affinity tography matrix comprises a second affinity reagent sing a biotin, the second affinity reagent thereby being suitable for immobilizing the multimerization reagent on the second stationary phase, (d) the ctor and the first stationary phase are fluidly connected, and (e) the first stationary phase and the second stationary phase are fluidly connected.
2. The arrangement of claim 1, wherein the first affinity reagent ses streptavidin.
3. The arrangement of claim 1, wherein the first affinity reagent comprises a streptavidin mutein.
4. The arrangement of claim 1, wherein the first affinity reagent comprises a streptavidin mutein that comprises the amino acid sequence Val44-Thr45-Ala46-Arg47 at sequence positions 44 to 47 of wild type streptavidin or a streptavidin mutein that comprises the amino acid sequence Ile44-Gly45-Ala46-Arg47 at sequence positions 44 to 47 of wild type streptavidin.
5. The arrangement of any one of claims 1-4, wherein the second stationary phase and the bioreactor are fluidly ted to each other.
6. An arrangement of a bioreactor, a first stationary phase for chromatography, and a second nary phase for chromatography, wherein: (a) the bioreactor is suitable for the expansion of lymphocytes using a multimerization t capable of stimulating lymphocytes, wherein: (i) the multimerization reagent is in a soluble form and is ibly bound to a first agent comprising a streptavidin-binding peptide C1 and a second agent comprising a streptavidin-binding peptide C2, wherein the first agent binds to a receptor molecule on the surface of the lymphocytes to provide a primary tion signal to the lymphocytes, and the second agent binds to an ory molecule on the surface of the lymphocytes to stimulate an accessory signal in the lymphocytes, (ii) the erization reagent comprises streptavidin or a streptavidin mutein that reversibly binds to the streptavidin-binding peptides C1 and C2, (b) the first stationary phase is suitable for cell separation and removal of reagents, is comprised in a first chromatography column, and is a first gel filtration matrix and/or affinity chromatography matrix, wherein the first gel tion and/or affinity chromatography matrix comprises a first affinity reagent comprising a biotin, the first affinity reagent thereby being suitable for lizing the multimerization reagent on the first stationary phase, (c) the second stationary phase is comprised in a second chromatography column and is a second gel tion matrix and/or affinity chromatography matrix, wherein the second gel filtration and/or affinity chromatography matrix comprises a second affinity t comprising streptavidin or a streptavidin mutein capable of specifically binding to the streptavidin-binding peptide C1 and the streptavidin-binding peptide C2, the second affinity t thereby being suitable for immobilizing on the second stationary phase the first agent and the second agent, (d) the bioreactor and the first stationary phase are fluidly connected, and (e) the first stationary phase and the second stationary phase are y connected.
7. The arrangement of claim 6, wherein the second affinity reagent ses streptavidin.
8. The arrangement of claim 6, wherein the second affinity reagent comprises a streptavidin mutein.
9. The arrangement of claim 6, wherein the second affinity reagent comprises a streptavidin mutein that comprises the amino acid ce Val44-Thr45-Ala46-Arg47 at sequence positions 44 to 47 of wild type streptavidin or a streptavidin mutein that comprises the amino acid sequence Ile44-Gly45-Ala46-Arg47 at sequence positions 44 to 47 of wild type streptavidin.
10. An apparatus for purification and ion of lymphocytes, the apparatus comprising at least one arrangement of a bioreactor, a first stationary phase for chromatography, and a second stationary phase for tography as defined in any one of claims 1-9.
11. The apparatus of claim 10, comprising a sample inlet fluidly connected to the bioreactor.
12. The tus of claim 10 or claim 11, comprising a sample outlet for purified and expanded lymphocytes, the sample outlet being fluidly connected to the second stationary phase.
13. The apparatus of any one of claims 10-12, wherein the apparatus is a functionally closed system.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461980506P | 2014-04-16 | 2014-04-16 | |
US61/980,506 | 2014-04-16 | ||
NZ725213A NZ725213B2 (en) | 2014-04-16 | 2015-04-16 | Methods, kits and apparatus for expanding a population of cells |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ763587A NZ763587A (en) | 2021-11-26 |
NZ763587B2 true NZ763587B2 (en) | 2022-03-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220195388A1 (en) | Methods, kits and apparatus for expanding a population of cells | |
US20230295567A1 (en) | Methods for culturing cells and kits and apparatus for same | |
JP2018531035A6 (en) | Method for culturing cells and kit and apparatus therefor | |
NZ763587B2 (en) | Methods, kits and apparatus for expanding a population of cells | |
NZ763583B2 (en) | Methods, kits and apparatus for expanding a population of cells | |
NZ763585B2 (en) | Methods, kits and apparatus for expanding a population of cells | |
NZ725213B2 (en) | Methods, kits and apparatus for expanding a population of cells |